Teleflex (TFX) 10-Q 30 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 29, 2015	Apr. 20, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	29-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INC
Entity Central Index Key	96943
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		41,528,795

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Income Statement [Abstract]
Net revenues	$429,430	$438,546
Cost of goods sold	206,793	217,387
Gross profit	222,637	221,159
Selling, general and administrative expenses	139,697	140,297
Research and development expenses	12,884	14,062
Restructuring and impairment charges	4,448	7,780
Income from continuing operations before interest and taxes	65,608	59,020
Interest expense	17,172	15,404
Interest income	-169	-187
Income from continuing operations before taxes	48,605	43,803
Taxes on income from continuing operations	9,332	8,534
Income from continuing operations	39,273	35,269
Operating loss from discontinued operations	-499	-25
Taxes on loss from discontinued operations	204	100
Loss from discontinued operations	-703	-125
Net income	38,570	35,144
Less: Income from continuing operations attributable to noncontrolling interest	218	186
Net income attributable to common shareholders	38,352	34,958
Basic:
Income from continuing operations (in dollars per share)	$0.94	$0.85
Loss from discontinued operations (in dollars per share)	($0.02)	$0
Net income (in dollars per share)	$0.92	$0.85
Diluted:
Income from continuing operations (in dollars per share)	$0.83	$0.77
Loss from discontinued operations (in dollars per share)	($0.02)	($0.01)
Net income (in dollars per share)	$0.81	$0.76
Dividends per share (in dollars per share)	$0.34	$0.34
Weighted average common shares outstanding
Basic (in shares)	41,469	41,262
Diluted (in shares)	47,295	45,749
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	39,055	35,083
Loss from discontinued operations, net of tax	-703	-125
Net income attributable to common shareholders	$38,352	$34,958

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Statement of Comprehensive Income [Abstract]
Net income	$38,570	$35,144
Other comprehensive (loss) income, net of tax:
Foreign currency translation, net of tax of $23,438 and $(3,189)	-83,090	4,117
Pension and other postretirement benefit plans adjustment, net of tax of $(886) and $(503)	1,906	624
Derivatives qualifying as hedges, net of tax of $(25) and $(40)	44	70
Other comprehensive (loss) income, net of tax:	-81,140	4,811
Comprehensive (loss) income	-42,570	39,955
Less: comprehensive income attributable to non-controlling interest	279	252
Comprehensive (loss) income attributable to common shareholders	($42,849)	$39,703

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Statement of Comprehensive Income [Abstract]
Foreign Currency translation tax	$23,438	($3,189)
Pension and other postretirement benefits plans adjustment, tax	-886	-503
Derivatives qualifying as hedges, tax	($25)	($40)

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$308,759	$303,236
Accounts receivable, net	284,827	273,704
Inventories, net	338,736	335,593
Prepaid expenses and other current assets	40,935	35,697
Prepaid taxes	33,993	40,256
Deferred tax assets	56,562	57,301
Assets held for sale	6,959	7,422
Total current assets	1,070,771	1,053,209
Property, plant and equipment, net	310,106	317,435
Goodwill	1,293,506	1,323,553
Intangible assets, net	1,183,549	1,216,720
Investments in affiliates	734	1,150
Deferred tax assets	1,119	1,178
Other assets	63,810	64,010
Total assets	3,923,595	3,977,255
Current liabilities
Current borrowings	401,565	368,401
Accounts payable	75,310	64,100
Accrued expenses	71,905	72,383
Current portion of contingent consideration	7,462	11,276
Payroll and benefit-related liabilities	66,324	85,442
Accrued interest	12,855	9,169
Income taxes payable	17,558	13,768
Other current liabilities	11,446	10,360
Total current liabilities	664,425	634,899
Long-term borrowings	700,000	700,000
Deferred tax liabilities	426,768	451,541
Pension and postretirement benefit liabilities	162,595	167,241
Noncurrent liability for uncertain tax provisions	49,334	50,884
Other liabilities	59,871	58,991
Total liabilities	2,062,993	2,063,556
Commitments and contingencies
Total common shareholders' equity	1,857,933	1,911,309
Noncontrolling interest	2,669	2,390
Total equity	1,860,602	1,913,699
Total liabilities and equity	$3,923,595	$3,977,255

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Cash Flows from Operating Activities of Continuing Operations
Net income	$38,570	$35,144
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	703	125
Depreciation expense	10,915	11,580
Amortization expense of intangible assets	14,740	16,019
Amortization expense of deferred financing costs and debt discount	4,195	3,814
Changes in contingent consideration	382	-2,371
Stock-based compensation	3,832	3,074
Deferred income taxes, net	1,085	3,515
Other	-4,294	-3,105
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	-21,906	5,966
Inventories	-14,578	-7,473
Prepaid expenses and other current assets	-4,756	-6,027
Accounts payable and accrued expenses	3,819	-16,129
Income taxes receivable and payable, net	9,651	-2,214
Net cash provided by operating activities from continuing operations	42,358	41,918
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	-14,445	-12,109
Proceeds from sale of assets and investments	0	1,669
Payments for businesses and intangibles acquired, net of cash acquired	-7,375	-28,991
Investment in affiliates	0	-60
Net cash used in investing activities from continuing operations	-21,820	-39,491
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	30,000	0
Repayment of long-term borrowings	-52	0
Debt extinguishment, issuance and amendment fees	0	-90
Net proceeds from share based compensation plans and the related tax impacts	-289	323
Payments for contingent consideration	-3,989	0
Dividends	-14,118	-14,051
Net cash provided by (used in) financing activities from continuing operations	11,552	-13,818
Cash Flows from Discontinued Operations:
Net cash used in operating activities	-1,126	-1,167
Net cash used in discontinued operations	-1,126	-1,167
Effect of exchange rate changes on cash and cash equivalents	-25,441	2,223
Net decrease in cash and cash equivalents	5,523	-10,335
Cash and cash equivalents at the beginning of the period	303,236	431,984
Cash and cash equivalents at the end of the period	$308,759	$421,649

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Noncontrolling Interest
In Thousands, unless otherwise specified
Beginning Balance at Dec. 31, 2013	$1,916,016	$43,243	$409,338	$1,696,424	($110,855)	($124,623)	$2,489
Beginning Balance (in shares) at Dec. 31, 2013		43,243				2,064
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	35,144			34,958			186
Cash dividends (USD per share)	-14,051			-14,051
Other comprehensive (loss) income	4,811				4,745		66
Shares issued under compensation plans (in shares)		114				68
Settlements of convertible notes	3,226	114	641			2,471
Deferred compensation (in shares)						-2
Settlements of note hedges associated with convertible notes	81					81
Ending Balance at Mar. 30, 2014	1,945,227	43,357	409,979	1,717,331	-106,110	-122,071	2,741
Ending Balance (in shares) at Mar. 30, 2014		43,357				1,994
Beginning Balance at Dec. 31, 2014	1,913,699	43,420	422,394	1,827,845	-260,895	-121,455	2,390
Beginning Balance (in shares) at Dec. 31, 2014		43,420				1,981
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	38,570			38,352			218
Cash dividends (USD per share)	-14,118			-14,118
Other comprehensive (loss) income	-81,140				-81,201		61
Settlements of convertible notes	2		-22			24
Settlements of note hedges associated with convertible notes	0		43			-43
Shares issued under compensation plans (in shares)		31				55
Settlements of convertible notes	3,516	31	2,058			1,427
Deferred compensation (in shares)						-1
Settlements of note hedges associated with convertible notes	73					73
Ending Balance at Mar. 29, 2015	$1,860,602	$43,451	$424,473	$1,852,079	($342,096)	($119,974)	$2,669
Ending Balance (in shares) at Mar. 29, 2015		43,451				1,925

CONDENSED_CONSOLIDATED_STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$0.34	$0.34

Basis_of_presentation

Basis of presentation	3 Months Ended
	Mar. 29, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated are prepared on the same basis as the annual consolidated financial statements.
	In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.
	The Company’s share-based compensation plan permits employees to elect to have shares withheld by the Company to satisfy their minimum statutory tax withholding obligations arising from the exercise or vesting of share-based awards.  The Company then remits, in cash, the withholding taxes to the appropriate tax authorities on behalf of the employee.  For the three months ended March 29, 2015, the Company classified such payments as a cash outflow from financing activities and are reflected in the line item “Proceeds from share-based compensation plans and the related tax impacts” within the condensed consolidated statement of cash flows (i.e., the payment by the Company of the withholding taxes offsets, in part, increases in cash flow from financing activities resulting from the proceeds of the exercise and vesting of share-based awards and tax benefits related to such exercise and vesting).  In effect, the Company treats the activity as a repurchase of the employee’s shares.  The Company’s payments were previously reported as a cash outflow from operating activities; therefore, the Company reclassified the cash outflows of $8.3 million from operating to financing activities for the three months ended March 30, 2014 to conform to the current period presentation within the condensed consolidated statement of cash flows as well as the condensed consolidating statement of cash flows included in Note 15.
	As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

New_accounting_standards

New accounting standards	3 Months Ended
	Mar. 29, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards
	In May 2014, the Financial Accounting Standards Board (FASB), in a joint effort with the International Accounting Standards Board (IASB), issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In April 2015, the FASB proposed to defer the effective date of the new guidance. If the proposal is finalized, the guidance will become effective prospectively for annual periods beginning after December 15, 2017 and interim periods within those years; early application would be permitted for annual periods beginning after December 15, 2016. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows and financial position.
	In April 2015, FASB issued guidance for the reporting of debt issuance costs within the balance sheet. Under the new guidance, debt issuance costs are to be presented in the balance sheet as a direct deduction from the associated debt liability, consistent with the presentation of a debt discount. Currently, debt issuance costs are presented as a deferred charge (i.e., an asset) on the balance sheet. In addition to providing uniform treatment for debt issuance costs and debt discounts, the guidance is consistent with other FASB guidance, which states that debt issuance costs are similar to debt discounts because they reduce the proceeds of borrowing (thereby increasing the effective interest rate) and cannot be an asset because they provide no future economic benefit. The new guidance is effective for fiscal years beginning after December 15, 2015 with early adoption permitted, and is required to be applied on a retrospective basis. The Company does not believe that the adoption of this guidance will have a material impact on the Company’s financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 29, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions
	On January 20, 2015, the Company acquired Human Medics Co., Ltd., (“Human Medics”), a distributor of medical devices and supplies primarily in the Korean market and accounted for the acquisition as a business combination. The total fair value of consideration was $8.9 million, which included an initial payment of $7.4 million in cash and $1.8 million in future obligations, partially offset by a $0.3 million favorable working capital adjustment. Transaction expenses associated with the acquisition, which are included in selling, general and administrative expenses on the condensed consolidated statements of income, were $0.3 million for the three months ended March 29, 2015.
	The Company made the following acquisitions during 2014, which were accounted for as business combinations:
	•	On February 3, 2014, the Company acquired Mayo Healthcare Pty Limited, ("Mayo Healthcare"), a distributor of medical devices and supplies primarily in the Australian market.
	•	On December 2, 2014, the Company acquired the assets of Mini-Lap Technologies, Inc. ("Mini-Lap"), a developer of micro-laparoscopic instrumentation, which complements the Company's surgical product portfolio.
	The total fair value of consideration for the 2014 acquisitions was $66.3 million. The results of operations of the acquired businesses and assets are included in the consolidated statements of income from their respective acquisition dates. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring_and_impairment_c

Restructuring and impairment charges	3 Months Ended
	Mar. 29, 2015
Restructuring and Related Activities [Abstract]
Restructuring and impairment charges	Restructuring and impairment charges
	2015 Restructuring Plans
	During the first quarter 2015, the Company committed to programs associated with the reorganization of certain of its businesses as discussed in Note 14 and the consolidation of certain facilities in North America. The Company estimates that it will record pre-tax charges of $6 million to $7 million related to these programs, which represent employee termination benefits, contract termination costs and facility closure and other exit costs and will result in future cash outlays. For the three months ended March 29, 2015, the Company recorded charges of $4.2 million related to these programs. As of March 29, 2015, the Company has a reserve of $4.1 million related to these plans.
	2014 Manufacturing Footprint Realignment Plan
	On April 28, 2014, the Board of Directors approved a restructuring plan (the “2014 Manufacturing Footprint Realignment Plan”) involving the consolidation of operations and a related reduction in workforce at certain of the Company’s facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the quarter ended June 29, 2014 and are expected to be substantially completed by the end of 2017.
	The Company estimates that it will incur aggregate pre-tax charges in connection with these restructuring activities of approximately $37 million to $44 million, of which an estimated $26 million to $31 million are expected to result in future cash outlays. Most of these charges are expected to be incurred prior to the end of 2016.
	The following table provides a summary of the Company's current cost estimates by major type of expense associated with the 2014 Manufacturing Footprint Realignment Plan:
	Type of expense	Total estimated amount expected to be incurred
	Termination benefits	$11 million to $13 million
	Facility closure and other exit costs	$2 million to $3 million
	Accelerated depreciation charges	$10 million to $11 million
	Other	$14 million to $17 million
		$37 million to $44 million
	The Company recorded expenses of $2.3 million for the three months ended March 29, 2015 related to the 2014 Manufacturing Footprint Realignment Plan. Of this amount, $0.2 million was recorded as restructuring expense for the three months ended March 29, 2015, and $2.1 million related to accelerated depreciation and certain other costs resulting from the plan and was included in cost of goods sold. The Company incurred net aggregate restructuring and impairment charges over the term of this program of $9.4 million. Additionally, the Company incurred net aggregate accelerated depreciation and certain other costs, which were included in cost of sales, over the term of this program of $7.1 million. As of March 29, 2015, the Company has a restructuring reserve of $8.8 million in connection with this plan, all of which relates to termination benefits.
	As the 2014 Manufacturing Footprint Realignment Plan progresses, management will reevaluate the estimated expenses set forth above, and may revise its estimates, as appropriate, consistent with generally accepted accounting principles.
	2014 European Restructuring Plan
	On February 27, 2014, the Company committed to a restructuring plan (the “2014 European Restructuring Plan”), which impacts certain administrative functions in Europe and involves the consolidation of operations and a related reduction in workforce at certain of the Company’s European facilities.
	The Company recorded nominal charges for the three months ended March 29, 2015 with respect to this program. The Company incurred net aggregate restructuring and impairment charges over the term of this program of $7.8 million. As of March 29, 2015, the Company had a reserve of $0.4 million in connection with the 2014 European Restructuring Plan.  The Company expects to complete this plan in 2015.
	Other 2014 Restructuring Programs
	In June 2014, the Company initiated programs to consolidate locations in Australia and terminate certain distributor agreements in an effort to reduce costs. As a result of these actions, the Company expects to incur aggregate restructuring and impairment charges over the term of these restructuring programs of approximately $4 million, of which, $3.6 million was incurred through March 29, 2015. These programs include costs related to termination benefits, contract termination costs and other exit costs. As of March 29, 2015, the Company had a reserve of $0.9 million in connection with these programs. The Company expects to complete the programs in 2015.
	LMA Restructuring Program
	In connection with the acquisition of substantially all of the assets of LMA International N.V. (the “LMA business”) in 2012, the Company commenced a program (the "LMA Restructuring Program") related to the integration of the LMA business and the Company’s other businesses. The program focuses on the closure of the LMA business’ corporate functions and the consolidation of manufacturing, sales, marketing, and distribution functions in North America, Europe and Asia.
	As of March 29, 2015, the Company incurred net aggregate restructuring and impairment charges over the term of this program of $11.3 million. The Company expects future restructuring expenses associated with this program, if any, to be nominal. As of March 29, 2015, the Company had a reserve of $0.1 million associated with this program. The Company expects to complete the program in 2015.
	2013 Restructuring Charges
	In 2013, the Company initiated restructuring programs to consolidate administrative and manufacturing facilities in North America and warehouse facilities in Europe and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company has incurred an aggregate of $11.1 million in restructuring and impairment charges over the term of these restructuring programs. These programs entail costs related to termination benefits, contract termination costs and charges related to post-closing obligations associated with its acquired businesses. Future restructuring expenses associated with these programs are expected to be nominal. As of March 29, 2015, the Company has a reserve of $0.8 million in connection with these programs. The Company expects to complete the programs in 2015.
	2012 Restructuring Program
	In 2012, the Company identified opportunities to improve its supply chain strategy by consolidating its three North American warehouses into one centralized warehouse; and lower costs and improve operating efficiencies through the termination of certain distributor agreements in Europe, the closure of certain North American facilities and workforce reductions. As of March 29, 2015, the Company has incurred net aggregate restructuring and impairment charges of $6.4 million over the term of this program, and expect future restructuring expenses associated with the program, if any, to be nominal. As of March 29, 2015, the Company has a reserve of $0.5 million in connection with the program. The Company expects to complete this program in 2015.
	Impairment Charges
	There were no impairment charges recorded for the three months ended March 29, 2015 or March 30, 2014.
	The restructuring and impairment charges recognized for the three months ended March 29, 2015 and March 30, 2014 consisted of the following:
	Three Months Ended March 29, 2015
	(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
	2015 Restructuring programs	$	3,550		$	67		$	621		$	—	$	4,238
	2014 Manufacturing footprint realignment plan	137			22			—			4		163
	2014 European restructuring plan	9			—			—			17		26
	Other 2014 restructuring programs	—			—			49			—		49
	LMA restructuring program	—			—			(31		)	—		(31		)
	2013 Restructuring programs	3			—			—			—		3
	Total restructuring and impairment charges	$	3,699		$	89		$	639		$	21	$	4,448
	Three Months Ended March 30, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	—		$	42		$	(472	)	$	—	$	(430	)
	2014 European restructuring program	8,318			—			—			—		8,318
	2013 Restructuring programs	168			—			—			—		168
	2012 Restructuring program	(610		)	320			—			—		(290		)
	2011 Restructuring program	—			14			—			—		14
	Total restructuring and impairment charges	$	7,876		$	376		$	(472	)	$	—	$	7,780
	Termination benefits include estimated employee retention, severance and benefit payments for terminated employees.
	Facility closure costs include general operating costs incurred subsequent to production shut-down as well as equipment relocation and other associated costs.
	Contract termination costs include costs associated with terminating existing leases and distributor agreements.
	Other costs include legal, outplacement and employee relocation costs and other employee-related costs.
	Restructuring and impairment charges by reportable segment for the three months ended March 29, 2015 and March 30, 2014 are set forth in the following table:
		Three Months Ended
		March 29, 2015			March 30, 2014
		(Dollars in thousands)
	Restructuring and impairment charges
	Vascular North America	$	830		$	14
	Anesthesia/Respiratory North America	(40		)	27
	Surgical North America	23			—
	EMEA	(32		)	7,889
	Asia	—			78
	OEM	—			—
All other	3,667			(228		)
Total restructuring and impairment charges	$	4,448		$	7,780

Inventories_net

Inventories, net	3 Months Ended
	Mar. 29, 2015
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net
	Inventories as of March 29, 2015 and December 31, 2014 consisted of the following:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Raw materials	$	70,285		$	68,191
	Work-in-process	57,205			58,526
	Finished goods	244,814			242,750
		372,304			369,467
	Less: inventory reserve	(33,568		)	(33,874		)
	Inventories, net	$	338,736		$	335,593

Goodwill_and_other_intangible_

Goodwill and other intangible assets, net	3 Months Ended
	Mar. 29, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Goodwill and other intangible assets, net
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the three months ended March 29, 2015:
		Vascular			Anesthesia/			Surgical			EMEA			Asia			All			Total
		North America			Respiratory			North America									Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2014
	Goodwill	$	459,696		$	166,514		$	250,912		$	339,029		$	144,712		$	294,818		$	1,655,681
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		240,169			59,441			250,912			339,029			144,712			289,290			1,323,553
	Goodwill related to acquisitions	—			—			—			—			2,801			—			2,801
	Translation adjustment	—			(516		)	—			(28,541		)	(3,628		)	(163		)	(32,848		)
	Balance at March 29, 2015
	Goodwill	459,696			165,998			250,912			310,488			143,885			294,655			1,625,634
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		$	240,169		$	58,925		$	250,912		$	310,488		$	143,885		$	289,127		$	1,293,506
	The following table provides information as of March 29, 2015 and December 31, 2014 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		29-Mar-15			31-Dec-14			29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Customer relationships	$	616,788		$	624,574		$	(196,679	)	$	(192,876	)
	In-process research and development	41,000			68,694			—			—
	Intellectual property	489,857			467,068			(151,521		)	(146,131		)
	Distribution rights	15,519			16,101			(13,751		)	(14,243		)
	Trade names	386,194			396,269			(3,858		)	(2,764		)
	Non-compete agreements	337			337			(337		)	(309		)
		$	1,549,695		$	1,573,043		$	(366,146	)	$	(356,323	)
	In May 2012, the Company acquired Semprus BioSciences, a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications.  The Company experienced difficulties with respect to the development of the Semprus technology, and devoted further research and testing towards attempting to resolve the issue. As a result of these efforts, the Company believes it has resolved the issue and is focused on seeking regulatory approval and engaging in additional research and development efforts to achieve commercialization of this technology. Despite this progress, significant challenges to commercialization of the Semprus technology remain, and the Company ultimately may find it necessary to recognize future impairment charges with respect to the related assets, which could be material. As of March 29, 2015, the Company has in-process research and development ("IPR&D") intangible assets of $41.0 million related to this investment which are recorded in intangible assets, net.
	During the first quarter 2015, certain previously acquired research and development projects were completed and the related IPR&D assets of $27.6 million, which were previously classified as indefinite lived intangible assets, were reclassified to finite-lived intangible assets subject to amortization, specifically, intellectual property; therefore, the Company commenced amortization of these assets. The assets are being amortized over their estimated useful lives, which range from 7 to 18 years.
	Also during the first quarter 2015, the Company reassessed the useful life of one of its trade names, which had a carrying value of $61.5 million, and reclassified it from an indefinite lived intangible asset to a finite lived intangible asset with an estimated useful life of 20 years.
	Amortization expense related to intangible assets was $14.7 million and $16.0 million for the three months ended March 29, 2015 and March 30, 2014, respectively. Estimated annual amortization expense for the remainder of 2015 and the next five succeeding years is as follows (dollars in thousands):
	2015	$	43,600
	2016	59,500
	2017	59,000
	2018	58,700
	2019	58,400
	2020	58,200

Borrowings

Borrowings	3 Months Ended
	Mar. 29, 2015
Debt Disclosure [Abstract]
Borrowings	Borrowings
	The Company's borrowings at March 29, 2015 and December 31, 2014 are as follows:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 1.92% at March 29, 2015, due 2018	$	200,000		$	200,000
	3.875% Convertible Senior Subordinated Notes due 2017	399,846			399,898
	6.875% Senior Subordinated Notes due 2019	250,000			250,000
	5.25% Senior Notes due 2024	250,000			250,000
	Securitization program, at a rate of 0.93% at March 29, 2015	34,700			4,700
		1,134,546			1,104,598
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	(32,981		)	(36,197		)
		1,101,565			1,068,401
	Current borrowings	(401,565		)	(368,401		)
	Long-term borrowings	$	700,000		$	700,000
	Classification of 3.875% Convertible Notes as a Current Liability
	The Company's 3.875% Convertible Notes due 2017 (the "Convertible Notes") are convertible into shares of the Company's common stock at the option of the holder upon the occurrence of any of the following circumstances (i) during any fiscal quarter, if the last reported sale price of the Company’s common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price on each applicable trading day; or (ii) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of Convertible Notes is less than 98% of the product of the last reported sale price of the common stock and the applicable conversion rate on each trading day during the measurement period; or (iii) upon the occurrence of specified corporate events; or (iv) at any time on or after May 1, 2017 up to and including July 28, 2017. The Convertible Notes are convertible at a conversion rate of 16.3084 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to a conversion price of approximately $61.32 per share. The conversion rate is subject to adjustment upon certain events. Upon conversion, the Company’s conversion obligation may be satisfied, at the Company’s option, in shares of common stock, cash or a combination of cash and shares of common stock. The Company has elected a net-settlement method to satisfy its conversion obligation. Under the net-settlement method, the Company will settle the $1,000 principal amount of the Convertible Notes in cash and settle the excess conversion value in shares, plus cash in lieu of fractional shares.
	Since the fourth quarter 2013, the Company's last reported sale price has exceeded the 130% threshold described above and accordingly the Convertible Notes have been classified as a current liability as of March 29, 2015 and December 31, 2014. The determination of whether or not the Convertible Notes are convertible as described above is made each quarter until maturity, conversion or repurchase.  Consequently, it is possible that the Convertible Notes may not be convertible in one or more future quarters, in which case the Convertible Notes would again be classified as long-term debt, unless one of the other conversion contingencies described above were to be satisfied. While the Company believes it has sufficient liquidity to repay the principal amount due through a combination of utilizing its existing cash on hand and accessing its credit facility, the Company's use of these funds could adversely affect its results of operations and liquidity.
	Redemption of 6.875% Senior Subordinated Notes due 2019
	On April 30, 2015, the Company issued a notice of redemption to holders of its outstanding $250 million aggregate principal amount of 6.875% Senior Subordinated Notes due 2019 (the “2019 Notes”).  Pursuant to the notice of redemption, the 2019 Notes will be redeemed on June 1, 2015 (the “Redemption Date”) at a redemption price equal to 103.438% of the principal amount of the 2019 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”).  The notice of redemption provides that the redemption is subject to the condition that the Company is able to borrow funds under its revolving credit agreement on the Redemption Date in an amount sufficient to pay the aggregate Redemption Price.
	Fair Value of Long-Term Debt
	The carrying amount of long-term debt reported in the condensed consolidated balance sheet as of March 29, 2015 is $1,101.6 million. To determine the fair value of its debt, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of March 29, 2015, categorized by the level of inputs, within the fair value hierarchy, used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2014 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	1,040,170
	Level 2	494,596
	Total	$	1,534,766

Financial_instruments

Financial instruments	3 Months Ended
	Mar. 29, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Financial instruments
	The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the condensed consolidated balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive (loss) income and thereafter is recognized in the condensed consolidated statement of income in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the condensed consolidated statement of income in the period in which such gains and losses occur.
	The following table presents the location and fair value of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of March 29, 2015 and December 31, 2014:
		29-Mar-15			31-Dec-14
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign currency forward contracts:
	Prepaid expenses and other current assets	$	1,737		$	—
	Total asset derivatives	$	1,737		$	—
	Liability derivatives:
	Foreign currency forward contracts:
	Other current liabilities	$	1,553		$	—
	Total liability derivatives	$	1,553		$	—
	The total notional amount for all open foreign currency forward contracts as of March 29, 2015 is approximately $99.6 million. As of December 31, 2014, the Company had no open foreign currency forward contracts.
	The following table provides information as to the gains attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive (loss) income (“OCI”) for the three months ended March 29, 2015 and March 30, 2014:
		After Tax Gain
		Recognized in OCI
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Foreign currency forward contracts	$	44		$	70
	Total	$	44		$	70
	See Note 10 for information on the location and amount of gains attributable to derivatives that were reclassified from accumulated other comprehensive (loss) income (“AOCI”) to expense (income), net of tax.
	There was no ineffectiveness related to the Company’s derivatives during the three months ended March 29, 2015 and March 30, 2014.
	Based on exchange rates at March 29, 2015, approximately $0.1 million of unrealized gains, net of tax, within AOCI are expected to be reclassified from AOCI to the condensed consolidated statement of income during the remainder of 2015. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates.
	Concentration of Credit Risk
	Concentrations of credit risk with respect to trade accounts receivable is generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the creditworthiness of those countries’ and the financial stability of their economies.
	In the ordinary course of business, the Company grants non-interest bearing trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of its customers’ financial condition, (iii) monitors the payment history and aging of its customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.
	An allowance for doubtful accounts is maintained for accounts receivable based on the Company’s historical collection experience and expected collectability of the accounts receivable, considering the period an account is outstanding, the financial position of the customer and information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. The allowance for doubtful accounts was $8.3 million and $8.8 million at March 29, 2015 and December 31, 2014, respectively. The current portion of the allowance for doubtful accounts at March 29, 2015 and December 31, 2014 of $2.3 million and $2.4 million, respectively, is reflected in accounts receivable, net. The allowance for doubtful accounts on receivables outstanding for greater than one year at March 29, 2015 and December 31, 2014 of $6.0 million and $6.4 million, respectively, is reflected in other assets.
	In light of the disruptions in global economic markets, the Company instituted enhanced measures, within countries where the Company has collectability concerns, to facilitate customer-by-customer risk assessment when estimating the allowance for doubtful accounts. Such measures include, among others, monthly credit control committee meetings, at which customer credit risks are identified after review of, among other things, accounts that exceed specified credit limits, payment delinquencies and other customer issues. In addition, for some of the Company’s non-government customers, the Company instituted measures designed to reduce its risk exposures, including issuing dunning letters, reducing credit limits, requiring that payments accompany orders and instituting legal action with respect to delinquent accounts. With respect to government customers, the Company evaluates receivables for potential collection risks associated with the availability of government funding and reimbursement practices.
	Certain of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal. As a result, the Company increased the allowance for doubtful accounts related to these customers. If the financial condition of these customers or the healthcare systems in these countries deteriorate to the extent that the ability of an increasing number of customers to satisfy their payment obligations is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term accounts receivable represented by the net current and long-term accounts receivable for customers in those countries at March 29, 2015 and December 31, 2014 are as follows:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $7.1 million and $8.1 million at March 29, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1)	$	76,322		$	76,190
	Percentage of total net current and long-term accounts receivable	26.6		%	27.3		%
	(1)The long-term portion of accounts receivable, net from customers in Greece, Italy, Spain and Portugal at March 29, 2015 and December 31, 2014 was $10.3 million and $11.3 million, respectively, and is reported on the condensed consolidated balance sheet in other assets.
	For the three months ended March 29, 2015 and March 30, 2014, net revenues from customers in Greece, Italy, Spain and Portugal were $33.0 million and $39.3 million, respectively.

Fair_value_measurement

Fair value measurement	3 Months Ended
	Mar. 29, 2015
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement
	For a description of the fair value hierarchy, see Note 10 to the Company’s 2014 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2014.
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of March 29, 2015 and December 31, 2014:
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		29-Mar-15			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,954		$	6,954	$	—	$	—
	Derivative assets	1,737			—		1,737		—
	Derivative liabilities	1,553			—		1,553		—
	Contingent consideration liabilities	29,825			—		—		29,825
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		December 31, 2014			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,863		$	6,863	$	—	$	—
	Contingent consideration liabilities	33,433			—		—		33,433
	There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the three months ended March 29, 2015.
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the three months ended March 29, 2015:
		Contingent consideration
		2015
		(Dollars in thousands)
	Balance - December 31, 2014	$	33,433
	Payment	(4,000		)
	Revaluations	392
	Balance - March 29, 2015	$	29,825
	Valuation Techniques
	The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices.
	The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage currency transaction exposure. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties.
	The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company accounts for contingent consideration in accordance with applicable accounting guidance related to business combinations. In connection with several of its acquisitions, the Company agreed to pay contingent consideration upon the achievement of specified objectives, including receipt of regulatory approvals, achievement of sales targets and, in some instances, the passage of time, and recorded contingent consideration liabilities at the time of the acquisitions. The Company determines the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration liability associated with future payments under contingent consideration arrangements is based on several factors including:
	l	estimated cash flows projected from the success of market launches;
	l	the estimated time and resources needed to complete the development of acquired technologies;
	l	the uncertainty of obtaining regulatory approvals within the required time periods; and
	l	the risk adjusted discount rate for fair value measurement.
	In connection with the Company's contingent consideration arrangements, the Company estimates that it will make payments in 2015 through 2029. As of March 29, 2015, the range of undiscounted amounts the Company could be required to pay under contingent consideration arrangements is between $11.0 million and $78.9 million. The Company is required to reevaluate the fair value of contingent consideration each reporting period based on new developments and record changes in fair value until such consideration is satisfied through payment upon the achievement of the specified objectives or is no longer payable due to failure to achieve the specified objectives.
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of March 29, 2015:
		Valuation Technique		Unobservable Input	Range (Weighted Average)
	Contingent consideration	Discounted cash flow		Discount rate	1.7% - 10% (7.3%)
				Probability of payment	0% - 100% (50.2%)
	As of March 29, 2015, the Company recorded $29.8 million of total liabilities for contingent consideration, of which $7.5 million and $22.3 million were recorded as the current portion of contingent consideration and other liabilities, respectively, in the condensed consolidated balance sheet.

Changes_in_shareholders_equity

Changes in shareholders' equity Changes in shareholders' equity	3 Months Ended
	Mar. 29, 2015
Equity [Abstract]
Changes in shareholders' equity	Changes in shareholders’ equity
	Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended
		March 29, 2015			March 30, 2014
		(Shares in thousands)
	Basic	41,469			41,262
	Dilutive effect of share-based awards	467			471
	Dilutive effect of 3.875% Convertible Notes and warrants	5,359			4,016
	Diluted	47,295			45,749
	Weighted average shares that were antidilutive and therefore not included in the calculation of earnings per share were approximately 5.8 million and 6.5 million for the three months ended March 29, 2015 and March 30, 2014, respectively.
	During periods in which the average market price of the Company's common stock is above the applicable conversion price of the Convertible Notes, or $61.32 per share, the impact of conversion would be dilutive and the dilutive effect of conversion of the Convertible Notes is reflected in diluted earnings per share. As described in Note 7, the Company has elected the net settlement method of accounting for these conversions, under which the Company will settle the principal amount of the Convertible Notes in cash, and settle the excess conversion value in shares. As a result, in these periods, under the treasury stock method, the Company calculates the number of shares issuable under the terms of the Convertible Notes based on the average market price of the stock during the period, and includes that number in the total diluted shares outstanding for the period.
	In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge economically reduces the dilutive impact of the Convertible Notes. However, applicable accounting guidance requires the Company to separately analyze the impact of the warrant agreements on diluted weighted average shares outstanding, while excluding the impact of the convertible note hedge agreements because it would be anti-dilutive. The reductions in diluted shares that would result from including the anti-dilutive impact of the convertible note hedges would have been 3.1 million and 2.5 million for the three months ended March 29, 2015 and March 30, 2014, respectively. The treasury stock method is applied when the warrants are in-the-money and assumes the proceeds from the exercise of the warrants are used to repurchase shares based on the average stock price during the period. The strike price of the warrants is approximately $74.65 per share of common stock. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 2.3 million and 1.6 million for the three months ended March 29, 2015 and March 30, 2014, respectively.
	In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generation from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio (generally, the ratio of Consolidated Total Indebtedness to Consolidated EBITDA, as defined in the senior credit agreements) exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through March 29, 2015, no shares have been purchased under this Board authorization.
	The following tables provide information relating to the changes in accumulated other comprehensive (loss) income, net of tax, for the three months ended March 29, 2015 and March 30, 2014:
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
		(Dollars in thousands)
	Balance as of December 31, 2014	$	—			$	(141,744	)	$	(119,151	)	$	(260,895	)
	Other comprehensive income (loss) before reclassifications	243				810			(83,151		)	(82,098		)
	Amounts reclassified from accumulated other comprehensive (loss) income	(199		)		1,096			—			897
	Net current-period other comprehensive income (loss)	44				1,906			(83,151		)	(81,201		)
	Balance at March 29, 2015	$	44			$	(139,838	)	$	(202,302	)	$	(342,096	)
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
		(Dollars in thousands)
	Balance at December 31, 2013	$	—			$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss) before reclassifications	113				(159		)	4,051			4,005
	Amounts reclassified from accumulated other comprehensive (loss) income	(43		)		783			—			740
	Net current-period other comprehensive income	70				624			4,051			4,745
	Balance at March 30, 2014	$	70			$	(96,413	)	$	(9,767	)	$	(106,110	)
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		29-Mar-15				30-Mar-14
		(Dollars in thousands)
	(Gains) losses on foreign exchange contracts:
	Cost of goods sold	$	(209	)		$	(77	)
	Total before tax	(209		)		(77		)
	Tax benefit	10				34
	Net of tax	$	(199	)		$	(43	)
	Amortization of pension and other postretirement benefit items:
	Actuarial losses (1)	$	1,606			$	1,102
	Prior-service costs(1)	—				(5		)
	Total before tax	1,606				1,097
	Tax expense	(510		)		(314		)
	Net of tax	$	1,096			$	783
	Total reclassifications, net of tax	$	897			$	740
	-1	These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin

Taxes on income from continuing operations	3 Months Ended
	Mar. 29, 2015
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Taxes on income from continuing operations
	The effective income tax rates for the three months ended March 29, 2015 and March 30, 2014 are as follows:
		Three Months Ended
		29-Mar-15	30-Mar-14
	Effective income tax rate	19.20%	19.50%
	The effective income tax rate for the three months ended March 29, 2015 and March 30, 2014 was 19.2% and 19.5%, respectively. There were no significant events impacting the effective tax rate for the three months ended March 29, 2015.

Pension_and_other_postretireme

Pension and other postretirement benefits	3 Months Ended
	Mar. 29, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits
	The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of March 29, 2015, the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement, are frozen.
	The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds.
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended
		29-Mar-15			30-Mar-14			29-Mar-15		30-Mar-14
		(Dollars in thousands)
	Service cost	$	471		$	450		$	107	$	138
	Interest cost	4,486			4,483			512		597
	Expected return on plan assets	(6,425		)	(6,260		)	—		—
	Net amortization and deferral	1,530			1,071			77		26
	Net benefit expense (income)	$	62		$	(256	)	$	696	$	761
	The Company’s pension contributions are expected to be approximately $2.9 million during 2015, of which $1.2 million were made during the three months ended March 29, 2015.

Commitments_and_contingent_lia

Commitments and contingent liabilities	3 Months Ended
	Mar. 29, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities
	Operating leases: The Company uses various leased facilities and equipment in its operations.
	Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.
	Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At March 29, 2015 the Company has recorded $1.1 million in accrued liabilities and $6.5 million, in other liabilities relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of March 29, 2015. The time frame, over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.
	Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. As of March 29, 2015, the Company accrued liabilities of $5.0 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Of the amount accrued as of March 29, 2015, $1.5 million pertains to discontinued operations.
	In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company has filed post-trial motions seeking to overturn the verdict or reduce the amount of damages, which the Company believes are excessive. If the Court denies the motions, the Company intends to pursue an appeal. As of March 29, 2015, the Company has accrued a liability representing its best estimate of any probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations discussed in the preceding paragraph. The Company believes that any liability arising from this matter in excess of $10.0 million will be covered by the Company’s product liability insurance.
	Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred.
	Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of March 29, 2015, the most significant tax examinations in process are in Austria, Canada, Germany and the United States. In conjunction with these examinations and as a regular and routine practice, the Company may establish reserves or adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.
	Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Business_segment_information

Business segment information	3 Months Ended
	Mar. 29, 2015
Segment Reporting [Abstract]
Business segment information	Business segment information
	An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The Company does not evaluate its operating segments using discrete asset information.
	The Company’s reportable segments, other than the Original Equipment Manufacturer and Development Services ("OEM") segment, design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
	The following tables present the Company’s segment results for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Revenue
	Vascular North America	$	67,913		$	62,506
	Anesthesia/Respiratory North America	55,390			54,714
	Surgical North America	38,059			35,231
	EMEA	129,282			150,245
	Asia	48,529			49,602
	OEM	34,715			33,182
	All other	55,542			53,066
	Consolidated net revenues	$	429,430		$	438,546
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Operating profit
	Vascular North America	$	12,702		$	9,392
	Anesthesia/Respiratory North America	7,752			5,687
	Surgical North America	12,327			10,548
	EMEA	26,335			26,881
	Asia	8,146			12,837
	OEM	8,043			6,604
	All other	8,349			9,768
	Total segment operating profit (1)	83,654			81,717
	Unallocated expenses (2)	(18,046		)	(22,697		)
	Income from continuing operations before interest and taxes	$	65,608		$	59,020
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges.
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Depreciation and amortization
	Vascular North America	$	8,477		$	7,855
	Anesthesia/Respiratory North America	3,195			4,428
	Surgical North America	2,478			2,369
	EMEA	7,898			8,937
	Asia	2,398			1,838
	OEM	1,667			1,456
	All other	3,737			4,530
	Consolidated depreciation and amortization	$	29,850		$	31,413
	Effective April 1, 2015, the Company reorganized certain of its businesses to better leverage the Company’s resources. As a result, the Company realigned its operating segments. Specifically, the Company's Anesthesia/Respiratory North America operating segment was split into two operating segments, Anesthesia North America and Respiratory North America. Additionally, the businesses comprising the Company's Specialty operating segment (which was not a reportable segment and, therefore, was included in the "All other" category in the Company's presentation of segment information) were transferred to the Anesthesia North America, Vascular North America and Respiratory North America operating segments.
	As a result of the operating segment changes described above, the Company has the following six reportable operating segments: Vascular North America, Anesthesia North America, Surgical North America, EMEA, Asia and OEM. In connection with its presentation of segment information, the Company will continue to present certain operating segments, including, among others, the Respiratory North America operating segment, in the “All other” category. In future filings, the Company will restate the operating segment results for prior comparative periods. Additionally, the segment realignment resulted in certain changes to the reporting unit structure and reallocation of goodwill to the new reporting units. Therefore, the Company will perform a goodwill impairment analysis of the affected reporting units during the second quarter 2015.
	Geographic data
	The following table provides total net revenues for the three months ended March 29, 2015 and March 30, 2014 and total net property, plant and equipment by geographic region as of March 29, 2015 and December 31, 2014:
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	231,206		$	216,461
	Other Americas	13,441			14,771
	Europe	140,682			168,775
	All other	44,101			38,539
		$	429,430		$	438,546
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	177,431		$	174,893
	Malaysia	36,173			36,427
	Czech Republic	32,541			35,655
	All other	63,961			70,460
	$	310,106		$	317,435

Condensed_consolidating_guaran

Condensed consolidating guarantor financial information	3 Months Ended
	Mar. 29, 2015
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information
	In June 2011, Teleflex Incorporated (referred to below as “Parent Company”) issued $250 million of its 6.875% senior subordinated notes due 2019 through a registered public offering. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive (loss) income for the three months ended March 29, 2015 and March 30, 2014, condensed consolidating balance sheets as of March 29, 2015 and December 31, 2014 and condensed consolidating statements of cash flows for the three months ended March 29, 2015 and March 30, 2014, provide consolidated information for:
	a.	Parent Company, the issuer of the guaranteed obligations;
	b.	Guarantor Subsidiaries, on a combined basis;
	c.	Non-guarantor subsidiaries, on a combined basis; and
	d.	Parent Company and its subsidiaries on a consolidated basis.
	The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidated financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation.
	Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE (LOSS) INCOME
		Three Months Ended March 29, 2015
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	264,161		$	258,901		$	(93,632	)	$	429,430
	Cost of goods sold	—			158,326			137,618			(89,151		)	206,793
	Gross profit	—			105,835			121,283			(4,481		)	222,637
	Selling, general and administrative expenses	11,452			84,268			43,817			160			139,697
	Research and development expenses	—			11,127			1,757			—			12,884
	Restructuring and impairment charges	—			3,739			709			—			4,448
	Income (loss) from continuing operations before interest, and taxes	(11,452		)	6,701			75,000			(4,641		)	65,608
	Interest expense	34,360			(18,569		)	1,381			—			17,172
	Interest income	—			—			(169		)	—			(169		)
	Income (loss) from continuing operations before taxes	(45,812		)	25,270			73,788			(4,641		)	48,605
	Taxes (benefit) on income from continuing operations	(15,293		)	10,992			10,804			2,829			9,332
	Equity in net income of consolidated subsidiaries	69,538			63,233			97			(132,868		)	—
	Income from continuing operations	39,019			77,511			63,081			(140,338		)	39,273
	Operating (loss) income from discontinued operations	(503		)	—			4			—			(499		)
	Taxes on loss from discontinued operations	164			—			40			—			204
	Loss from discontinued operations	(667		)	—			(36		)	—			(703		)
	Net income	38,352			77,511			63,045			(140,338		)	38,570
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			218			—			218
	Net income attributable to common shareholders	38,352			77,511			62,827			(140,338		)	38,352
	Other comprehensive loss attributable to common shareholders	(81,201		)	(106,761		)	(76,290		)	183,051			(81,201		)
	Comprehensive loss attributable to common shareholders	$	(42,849	)	$	(29,250	)	$	(13,463	)	$	42,713		$	(42,849	)
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	262,425		$	248,437		$	(72,316	)	$	438,546
	Cost of goods sold	—			152,368			137,873			(72,854		)	217,387
	Gross profit	—			110,057			110,564			538			221,159
	Selling, general and administrative expenses	10,778			81,395			47,921			203			140,297
	Research and development expenses	—			12,010			2,052			—			14,062
	Restructuring and impairment charges	—			(188		)	7,968			—			7,780
	Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(10,778		)	16,840			52,623			335			59,020
	Interest expense	33,726			(19,907		)	1,585			—			15,404
	Interest income	—			—			(187		)	—			(187		)
	Income (loss) from continuing operations before taxes	(44,504		)	36,747			51,225			335			43,803
	Taxes (benefit) on income from continuing operations	(15,420		)	17,218			8,832			(2,096		)	8,534
	Equity in net income of consolidated subsidiaries	64,124			43,108			94			(107,326		)	—
	Income from continuing operations	35,040			62,637			42,487			(104,895		)	35,269
	Operating loss from discontinued operations	(25		)	—			—			—			(25		)
	Taxes on loss from discontinued operations	57			—			43			—			100
	Loss from discontinued operations	(82		)	—			(43		)	—			(125		)
	Net income	34,958			62,637			42,444			(104,895		)	35,144
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			186			—			186
	Net income attributable to common shareholders	34,958			62,637			42,258			(104,895		)	34,958
	Other comprehensive income attributable to common shareholders	4,745			7,228			8,523			(15,751		)	4,745
	Comprehensive income attributable to common shareholders	$	39,703		$	69,865		$	50,781		$	(120,646	)	$	39,703
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING BALANCE SHEETS
		March 29, 2015
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
Company			Subsidiaries			Subsidiaries			Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	28,102		$	—		$	280,657		$	—		$	308,759
Accounts receivable, net	3,893			5,176			272,063			3,695			284,827
Accounts receivable from consolidated subsidiaries	10,159			2,197,884			266,150			(2,474,193		)	—
Inventories, net	—			206,295			159,769			(27,328		)	338,736
Prepaid expenses and other current assets	14,965			7,262			18,708			—			40,935
Prepaid taxes	21,149			—			12,844			—			33,993
Deferred tax assets	30,248			16,856			9,458			—			56,562
Assets held for sale	2,901			—			4,058			—			6,959
Total current assets	111,417			2,433,473			1,023,707			(2,497,826		)	1,070,771
Property, plant and equipment, net	3,329			172,767			134,010			—			310,106
Goodwill	—			703,664			589,842			—			1,293,506
Intangibles assets, net	—			734,111			449,438			—			1,183,549
Investments in affiliates	5,448,202			1,321,811			20,940			(6,790,219		)	734
Deferred tax assets	51,316			—			3,968			(54,165		)	1,119
Notes receivable and other amounts due from consolidated subsidiaries	1,206,846			1,566,089			189			(2,773,124		)	—
Other assets	29,392			6,836			27,582			—			63,810
Total assets	$	6,850,502		$	6,938,751		$	2,249,676		$	(12,115,334	)	$	3,923,595
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	366,865		$	—		$	34,700		$	—		$	401,565
Accounts payable	1,645			38,619			35,046			—			75,310
Accounts payable to consolidated subsidiaries	2,245,622			185,006			43,568			(2,474,196		)	—
Accrued expenses	18,174			24,052			29,679			—			71,905
Current portion of contingent consideration	—			7,462			—			—			7,462
Payroll and benefit-related liabilities	16,836			15,766			33,722			—			66,324
Accrued interest	12,792			—			63			—			12,855
Income taxes payable	—			—			17,558			—			17,558
Other current liabilities	1,672			5,089			4,685			—			11,446
Total current liabilities	2,663,606			275,994			199,021			(2,474,196		)	664,425
Long-term borrowings	700,000			—			—			—			700,000
Deferred tax liabilities	—			438,571			42,362			(54,165		)	426,768
Pension and other postretirement benefit liabilities	108,627			34,881			19,087			—			162,595
Noncurrent liability for uncertain tax positions	11,716			15,630			21,988			—			49,334
Notes payable and other amounts due from consolidated subsidiaries	1,486,644			1,129,731			157,293			(2,773,668		)	—
Other liabilities	21,976			25,204			12,691			—			59,871
Total liabilities	4,992,569			1,920,011			452,442			(5,302,029		)	2,062,993
Total common shareholders' equity	1,857,933			5,018,740			1,794,565			(6,813,305		)	1,857,933
Noncontrolling interest	—			—			2,669			—			2,669
Total equity	1,857,933			5,018,740			1,797,234			(6,813,305		)	1,860,602
Total liabilities and equity	$	6,850,502		$	6,938,751		$	2,249,676		$	(12,115,334	)	$	3,923,595
	December 31, 2014
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	27,996		$	—		$	275,240		$	—		$	303,236
Accounts receivable, net	2,346			2,422			265,081			3,855			273,704
Accounts receivable from consolidated subsidiaries	37,378			2,303,284			272,811			(2,613,473		)	—
Inventories, net	—			204,335			154,544			(23,286		)	335,593
Prepaid expenses and other current assets	14,301			4,786			16,610			—			35,697
Prepaid taxes	23,493			—			16,763			—			40,256
Deferred tax assets	30,248			17,387			9,666			—			57,301
Assets held for sale	2,901			—			4,521			—			7,422
Total current assets	138,663			2,532,214			1,015,236			(2,632,904		)	1,053,209
Property, plant and equipment, net	3,489			170,054			143,892			—			317,435
Goodwill	—			703,663			619,890			—			1,323,553
Intangibles assets, net	—			743,222			473,498			—			1,216,720
Investments in affiliates	5,662,773			1,359,661			21,253			(7,042,537		)	1,150
Deferred tax assets	52,244			—			5,535			(56,601		)	1,178
Notes receivable and other amounts due from consolidated subsidiaries	1,025,859			1,489,994			—			(2,515,853		)	—
Other assets	27,999			6,801			29,210			—			64,010
Total assets	$	6,911,027		$	7,005,609		$	2,308,514		$	(12,247,895	)	$	3,977,255
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	363,701		$	—		$	4,700		$	—		$	368,401
Accounts payable	1,449			32,692			29,959			—			64,100
Accounts payable to consolidated subsidiaries	2,259,891			188,908			163,291			(2,612,090		)	—
Accrued expenses	17,149			21,479			33,755			—			72,383
Current portion of contingent consideration	—			11,276			—			—			11,276
Payroll and benefit-related liabilities	20,693			27,228			37,521			—			85,442
Accrued interest	9,152			—			17			—			9,169
Income taxes payable	—			—			13,768			—			13,768
Other current liabilities	5			3,065			7,290			—			10,360
Total current liabilities	2,672,040			284,648			290,301			(2,612,090		)	634,899
Long-term borrowings	700,000			—			—			—			700,000
Deferred tax liabilities	—			462,274			45,867			(56,600		)	451,541
Pension and other postretirement benefit liabilities	110,830			35,074			21,337			—			167,241
Noncurrent liability for uncertain tax positions	11,431			15,569			23,884			—			50,884
Notes payable and other amounts due from consolidated subsidiaries	1,483,984			932,718			103,908			(2,520,610		)	—
Other liabilities	21,433			24,900			12,658			—			58,991
Total liabilities	4,999,718			1,755,183			497,955			(5,189,300		)	2,063,556
Total common shareholders' equity	1,911,309			5,250,426			1,808,169			(7,058,595		)	1,911,309
Noncontrolling interest	—			—			2,390			—			2,390
Total equity	1,911,309			5,250,426			1,810,559			(7,058,595		)	1,913,699
Total liabilities and equity	$	6,911,027		$	7,005,609		$	2,308,514		$	(12,247,895	)	$	3,977,255
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
	Three Months Ended March 29, 2015
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(55,153	)	$	(1,914	)	$	99,425		$	—		$	42,358
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	(37		)	(7,738		)	(6,670		)	—			(14,445		)
Proceeds from sale of assets and investments	—			—			—			—			—
Payments for businesses and intangibles acquired, net of cash acquired	—			—			(7,375		)	—			(7,375		)
Net cash used in investing activities from continuing operations	(37		)	(7,738		)	(14,045		)	—			(21,820		)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	30,000			—			—			—			30,000
Repayment of long-term borrowings	(52		)	—			—			—			(52		)
Net proceeds from share based compensation plans and the related tax impacts	(289		)	—			—			—			(289		)
Payments for contingent consideration	—			(3,989		)	—			—			(3,989		)
Dividends	(14,118		)	—			—			—			(14,118		)
Intercompany transactions	40,057			13,641			(53,698		)	—			—
Intercompany dividends paid	—			—			—			—			—
Net cash provided by (used in) financing activities from continuing operations	55,598			9,652			(53,698		)	—			11,552
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(302		)	—			(824		)	—			(1,126		)
Net cash used in discontinued  operations	(302		)	—			(824		)	—			(1,126		)
Effect of exchange rate changes on cash and cash equivalents	—			—			(25,441		)	—			(25,441		)
Net increase in cash and cash equivalents	106			—			5,417			—			5,523
Cash and cash equivalents at the beginning of the period	27,996			—			275,240			—			303,236
Cash and cash equivalents at the end of the period	$	28,102		$	—		$	280,657		$	—		$	308,759
	Three Months Ended March 30, 2014
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(22,185	)	$	24,438		$	39,665		$	—		$	41,918
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	(753		)	(4,823		)	(6,533		)	—			(12,109		)
Proceeds from sales of assets and investments	1,669			—			—			—			1,669
Payments for business intangibles acquired, net of cash acquired	—			—			(28,991		)	—			(28,991		)
Investments in affiliates	(60		)	—			—			—			(60		)
Net cash provided by (used in) investing activities from continuing operations	856			(4,823		)	(35,524		)	—			(39,491		)
Cash Flows from Financing Activities of Continuing Operations:
Debt extinguishment, issuance and amendment fees	(90		)	—			—			—			(90		)
Net proceeds from share based compensation plans and the related tax impacts	323			—			—			—			323
Dividends	(14,051		)	—			—			—			(14,051		)
Intercompany transactions	15,776			(28,602		)	12,826			—			—
Net cash provided by (used in) financing activities from continuing operations	1,958			(28,602		)	12,826			—			(13,818		)
Cash Flows from Discontinued Operations:													—
Net cash used in operating activities	(1,167		)	—			—			—			(1,167		)
Net cash used in discontinued operations	(1,167		)	—			—			—			(1,167		)
Effect of exchange rate changes on cash and cash equivalents	—			—			2,223			—			2,223
Net (decrease) increase in cash and cash equivalents	(20,538		)	(8,987		)	19,190			—			(10,335		)
Cash and cash equivalents at the beginning of the period	42,749			14,500			374,735			—			431,984
Cash and cash equivalents at the end of the period	22,211			5,513			393,925			—			421,649

New_accounting_standards_Polic

New accounting standards (Policies)	3 Months Ended
	Mar. 29, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards
	In May 2014, the Financial Accounting Standards Board (FASB), in a joint effort with the International Accounting Standards Board (IASB), issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In April 2015, the FASB proposed to defer the effective date of the new guidance. If the proposal is finalized, the guidance will become effective prospectively for annual periods beginning after December 15, 2017 and interim periods within those years; early application would be permitted for annual periods beginning after December 15, 2016. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows and financial position.
	In April 2015, FASB issued guidance for the reporting of debt issuance costs within the balance sheet. Under the new guidance, debt issuance costs are to be presented in the balance sheet as a direct deduction from the associated debt liability, consistent with the presentation of a debt discount. Currently, debt issuance costs are presented as a deferred charge (i.e., an asset) on the balance sheet. In addition to providing uniform treatment for debt issuance costs and debt discounts, the guidance is consistent with other FASB guidance, which states that debt issuance costs are similar to debt discounts because they reduce the proceeds of borrowing (thereby increasing the effective interest rate) and cannot be an asset because they provide no future economic benefit. The new guidance is effective for fiscal years beginning after December 15, 2015 with early adoption permitted, and is required to be applied on a retrospective basis. The Company does not believe that the adoption of this guidance will have a material impact on the Company’s financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Restructuring_and_other_impair

Restructuring and other impairment charges (Tables)	3 Months Ended
	Mar. 29, 2015
Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan	The following table provides a summary of the Company's current cost estimates by major type of expense associated with the 2014 Manufacturing Footprint Realignment Plan:
	Type of expense	Total estimated amount expected to be incurred
	Termination benefits	$11 million to $13 million
	Facility closure and other exit costs	$2 million to $3 million
	Accelerated depreciation charges	$10 million to $11 million
	Other	$14 million to $17 million
		$37 million to $44 million
Restructuring and Other Impairment Charges	Restructuring and impairment charges by reportable segment for the three months ended March 29, 2015 and March 30, 2014 are set forth in the following table:
		Three Months Ended
		March 29, 2015			March 30, 2014
		(Dollars in thousands)
	Restructuring and impairment charges
	Vascular North America	$	830		$	14
	Anesthesia/Respiratory North America	(40		)	27
	Surgical North America	23			—
	EMEA	(32		)	7,889
	Asia	—			78
	OEM	—			—
	All other	3,667			(228		)
	Total restructuring and impairment charges	$	4,448		$	7,780
	The restructuring and impairment charges recognized for the three months ended March 29, 2015 and March 30, 2014 consisted of the following:
	Three Months Ended March 29, 2015
	(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
	2015 Restructuring programs	$	3,550		$	67		$	621		$	—	$	4,238
	2014 Manufacturing footprint realignment plan	137			22			—			4		163
	2014 European restructuring plan	9			—			—			17		26
	Other 2014 restructuring programs	—			—			49			—		49
	LMA restructuring program	—			—			(31		)	—		(31		)
	2013 Restructuring programs	3			—			—			—		3
	Total restructuring and impairment charges	$	3,699		$	89		$	639		$	21	$	4,448
	Three Months Ended March 30, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	—		$	42		$	(472	)	$	—	$	(430	)
	2014 European restructuring program	8,318			—			—			—		8,318
	2013 Restructuring programs	168			—			—			—		168
	2012 Restructuring program	(610		)	320			—			—		(290		)
	2011 Restructuring program	—			14			—			—		14
	Total restructuring and impairment charges	$	7,876		$	376		$	(472	)	$	—	$	7,780

Inventories_net_Tables

Inventories, net (Tables)	3 Months Ended
	Mar. 29, 2015
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of March 29, 2015 and December 31, 2014 consisted of the following:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Raw materials	$	70,285		$	68,191
	Work-in-process	57,205			58,526
	Finished goods	244,814			242,750
		372,304			369,467
	Less: inventory reserve	(33,568		)	(33,874		)
	Inventories, net	$	338,736		$	335,593

Goodwill_and_other_intangible_1

Goodwill and other intangible assets, net (Tables)	3 Months Ended
	Mar. 29, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill, by Reporting Segment	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the three months ended March 29, 2015:
		Vascular			Anesthesia/			Surgical			EMEA			Asia			All			Total
		North America			Respiratory			North America									Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2014
	Goodwill	$	459,696		$	166,514		$	250,912		$	339,029		$	144,712		$	294,818		$	1,655,681
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		240,169			59,441			250,912			339,029			144,712			289,290			1,323,553
	Goodwill related to acquisitions	—			—			—			—			2,801			—			2,801
	Translation adjustment	—			(516		)	—			(28,541		)	(3,628		)	(163		)	(32,848		)
	Balance at March 29, 2015
	Goodwill	459,696			165,998			250,912			310,488			143,885			294,655			1,625,634
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		$	240,169		$	58,925		$	250,912		$	310,488		$	143,885		$	289,127		$	1,293,506
Components of Intangible Assets	The following table provides information as of March 29, 2015 and December 31, 2014 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		29-Mar-15			31-Dec-14			29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Customer relationships	$	616,788		$	624,574		$	(196,679	)	$	(192,876	)
	In-process research and development	41,000			68,694			—			—
	Intellectual property	489,857			467,068			(151,521		)	(146,131		)
	Distribution rights	15,519			16,101			(13,751		)	(14,243		)
	Trade names	386,194			396,269			(3,858		)	(2,764		)
	Non-compete agreements	337			337			(337		)	(309		)
		$	1,549,695		$	1,573,043		$	(366,146	)	$	(356,323	)
Estimated Annual Amortization Expense	Estimated annual amortization expense for the remainder of 2015 and the next five succeeding years is as follows (dollars in thousands):
	2015	$	43,600
	2016	59,500
	2017	59,000
	2018	58,700
	2019	58,400
	2020	58,200

Borrowings_Tables

Borrowings (Tables)	3 Months Ended
	Mar. 29, 2015
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at March 29, 2015 and December 31, 2014 are as follows:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 1.92% at March 29, 2015, due 2018	$	200,000		$	200,000
	3.875% Convertible Senior Subordinated Notes due 2017	399,846			399,898
	6.875% Senior Subordinated Notes due 2019	250,000			250,000
	5.25% Senior Notes due 2024	250,000			250,000
	Securitization program, at a rate of 0.93% at March 29, 2015	34,700			4,700
		1,134,546			1,104,598
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	(32,981		)	(36,197		)
		1,101,565			1,068,401
	Current borrowings	(401,565		)	(368,401		)
	Long-term borrowings	$	700,000		$	700,000
Fair Value of Long-Term Debt	The following table provides the fair value of the Company’s debt as of March 29, 2015, categorized by the level of inputs, within the fair value hierarchy, used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2014 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	1,040,170
	Level 2	494,596
	Total	$	1,534,766

Financial_instruments_Tables

Financial instruments (Tables)	3 Months Ended
	Mar. 29, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the location and fair value of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of March 29, 2015 and December 31, 2014:
		29-Mar-15			31-Dec-14
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign currency forward contracts:
	Prepaid expenses and other current assets	$	1,737		$	—
	Total asset derivatives	$	1,737		$	—
	Liability derivatives:
	Foreign currency forward contracts:
	Other current liabilities	$	1,553		$	—
	Total liability derivatives	$	1,553		$	—
After Tax Gain/(Loss) Recognized in OCI	The following table provides information as to the gains attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive (loss) income (“OCI”) for the three months ended March 29, 2015 and March 30, 2014:
		After Tax Gain
		Recognized in OCI
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Foreign currency forward contracts	$	44		$	70
	Total	$	44		$	70
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The aggregate net current and long-term accounts receivable for customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term accounts receivable represented by the net current and long-term accounts receivable for customers in those countries at March 29, 2015 and December 31, 2014 are as follows:
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $7.1 million and $8.1 million at March 29, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1)	$	76,322		$	76,190
	Percentage of total net current and long-term accounts receivable	26.6		%	27.3		%
	(1)The long-term portion of accounts receivable, net from customers in Greece, Italy, Spain and Portugal at March 29, 2015 and December 31, 2014 was $10.3 million and $11.3 million, respectively, and is reported on the condensed consolidated balance sheet in other assets

Fair_value_measurement_Tables

Fair value measurement (Tables)	3 Months Ended
	Mar. 29, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of March 29, 2015 and December 31, 2014:
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		29-Mar-15			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,954		$	6,954	$	—	$	—
	Derivative assets	1,737			—		1,737		—
	Derivative liabilities	1,553			—		1,553		—
	Contingent consideration liabilities	29,825			—		—		29,825
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		December 31, 2014			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,863		$	6,863	$	—	$	—
	Contingent consideration liabilities	33,433			—		—		33,433
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the three months ended March 29, 2015:
		Contingent consideration
		2015
		(Dollars in thousands)
	Balance - December 31, 2014	$	33,433
	Payment	(4,000		)
	Revaluations	392
	Balance - March 29, 2015	$	29,825
Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of March 29, 2015:
		Valuation Technique		Unobservable Input	Range (Weighted Average)
	Contingent consideration	Discounted cash flow		Discount rate	1.7% - 10% (7.3%)
				Probability of payment	0% - 100% (50.2%)

Changes_in_shareholders_equity1

Changes in shareholders' equity (Tables)	3 Months Ended
	Mar. 29, 2015
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended
		March 29, 2015			March 30, 2014
		(Shares in thousands)
	Basic	41,469			41,262
	Dilutive effect of share-based awards	467			471
	Dilutive effect of 3.875% Convertible Notes and warrants	5,359			4,016
	Diluted	47,295			45,749
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive (loss) income, net of tax, for the three months ended March 29, 2015 and March 30, 2014:
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
		(Dollars in thousands)
	Balance as of December 31, 2014	$	—			$	(141,744	)	$	(119,151	)	$	(260,895	)
	Other comprehensive income (loss) before reclassifications	243				810			(83,151		)	(82,098		)
	Amounts reclassified from accumulated other comprehensive (loss) income	(199		)		1,096			—			897
	Net current-period other comprehensive income (loss)	44				1,906			(83,151		)	(81,201		)
	Balance at March 29, 2015	$	44			$	(139,838	)	$	(202,302	)	$	(342,096	)
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive (Loss) Income
		(Dollars in thousands)
	Balance at December 31, 2013	$	—			$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss) before reclassifications	113				(159		)	4,051			4,005
	Amounts reclassified from accumulated other comprehensive (loss) income	(43		)		783			—			740
	Net current-period other comprehensive income	70				624			4,051			4,745
	Balance at March 30, 2014	$	70			$	(96,413	)	$	(9,767	)	$	(106,110	)
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		29-Mar-15				30-Mar-14
		(Dollars in thousands)
	(Gains) losses on foreign exchange contracts:
	Cost of goods sold	$	(209	)		$	(77	)
	Total before tax	(209		)		(77		)
	Tax benefit	10				34
	Net of tax	$	(199	)		$	(43	)
	Amortization of pension and other postretirement benefit items:
	Actuarial losses (1)	$	1,606			$	1,102
	Prior-service costs(1)	—				(5		)
	Total before tax	1,606				1,097
	Tax expense	(510		)		(314		)
	Net of tax	$	1,096			$	783
	Total reclassifications, net of tax	$	897			$	740
	-1	These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin1

Taxes on income from continuing operations (Tables)	3 Months Ended
	Mar. 29, 2015
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	The effective income tax rates for the three months ended March 29, 2015 and March 30, 2014 are as follows:
		Three Months Ended
		29-Mar-15	30-Mar-14
	Effective income tax rate	19.20%	19.50%

Pension_and_other_postretireme1

Pension and other postretirement benefits (Tables)	3 Months Ended
	Mar. 29, 2015
Compensation and Retirement Disclosure [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended
		29-Mar-15			30-Mar-14			29-Mar-15		30-Mar-14
		(Dollars in thousands)
	Service cost	$	471		$	450		$	107	$	138
	Interest cost	4,486			4,483			512		597
	Expected return on plan assets	(6,425		)	(6,260		)	—		—
	Net amortization and deferral	1,530			1,071			77		26
	Net benefit expense (income)	$	62		$	(256	)	$	696	$	761

Business_segment_information_T

Business segment information (Tables)	3 Months Ended
	Mar. 29, 2015
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Revenue
	Vascular North America	$	67,913		$	62,506
	Anesthesia/Respiratory North America	55,390			54,714
	Surgical North America	38,059			35,231
	EMEA	129,282			150,245
	Asia	48,529			49,602
	OEM	34,715			33,182
	All other	55,542			53,066
	Consolidated net revenues	$	429,430		$	438,546
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Operating profit
	Vascular North America	$	12,702		$	9,392
	Anesthesia/Respiratory North America	7,752			5,687
	Surgical North America	12,327			10,548
	EMEA	26,335			26,881
	Asia	8,146			12,837
	OEM	8,043			6,604
	All other	8,349			9,768
	Total segment operating profit (1)	83,654			81,717
	Unallocated expenses (2)	(18,046		)	(22,697		)
	Income from continuing operations before interest and taxes	$	65,608		$	59,020
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges.
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Depreciation and amortization
	Vascular North America	$	8,477		$	7,855
	Anesthesia/Respiratory North America	3,195			4,428
	Surgical North America	2,478			2,369
	EMEA	7,898			8,937
	Asia	2,398			1,838
	OEM	1,667			1,456
	All other	3,737			4,530
	Consolidated depreciation and amortization	$	29,850		$	31,413
Schedule of Revenues and Property Plant Equipment by Geographic Region	The following table provides total net revenues for the three months ended March 29, 2015 and March 30, 2014 and total net property, plant and equipment by geographic region as of March 29, 2015 and December 31, 2014:
		Three Months Ended
		29-Mar-15			30-Mar-14
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	231,206		$	216,461
	Other Americas	13,441			14,771
	Europe	140,682			168,775
	All other	44,101			38,539
		$	429,430		$	438,546
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country
		29-Mar-15			31-Dec-14
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	177,431		$	174,893
	Malaysia	36,173			36,427
	Czech Republic	32,541			35,655
	All other	63,961			70,460
		$	310,106		$	317,435

Condensed_consolidating_guaran1

Condensed consolidating guarantor financial information (Tables)	3 Months Ended
	Mar. 29, 2015
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE (LOSS) INCOME
		Three Months Ended March 29, 2015
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	264,161		$	258,901		$	(93,632	)	$	429,430
	Cost of goods sold	—			158,326			137,618			(89,151		)	206,793
	Gross profit	—			105,835			121,283			(4,481		)	222,637
	Selling, general and administrative expenses	11,452			84,268			43,817			160			139,697
	Research and development expenses	—			11,127			1,757			—			12,884
	Restructuring and impairment charges	—			3,739			709			—			4,448
	Income (loss) from continuing operations before interest, and taxes	(11,452		)	6,701			75,000			(4,641		)	65,608
	Interest expense	34,360			(18,569		)	1,381			—			17,172
	Interest income	—			—			(169		)	—			(169		)
	Income (loss) from continuing operations before taxes	(45,812		)	25,270			73,788			(4,641		)	48,605
	Taxes (benefit) on income from continuing operations	(15,293		)	10,992			10,804			2,829			9,332
	Equity in net income of consolidated subsidiaries	69,538			63,233			97			(132,868		)	—
	Income from continuing operations	39,019			77,511			63,081			(140,338		)	39,273
	Operating (loss) income from discontinued operations	(503		)	—			4			—			(499		)
	Taxes on loss from discontinued operations	164			—			40			—			204
	Loss from discontinued operations	(667		)	—			(36		)	—			(703		)
	Net income	38,352			77,511			63,045			(140,338		)	38,570
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			218			—			218
	Net income attributable to common shareholders	38,352			77,511			62,827			(140,338		)	38,352
	Other comprehensive loss attributable to common shareholders	(81,201		)	(106,761		)	(76,290		)	183,051			(81,201		)
	Comprehensive loss attributable to common shareholders	$	(42,849	)	$	(29,250	)	$	(13,463	)	$	42,713		$	(42,849	)
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	262,425		$	248,437		$	(72,316	)	$	438,546
	Cost of goods sold	—			152,368			137,873			(72,854		)	217,387
	Gross profit	—			110,057			110,564			538			221,159
	Selling, general and administrative expenses	10,778			81,395			47,921			203			140,297
	Research and development expenses	—			12,010			2,052			—			14,062
	Restructuring and impairment charges	—			(188		)	7,968			—			7,780
	Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(10,778		)	16,840			52,623			335			59,020
	Interest expense	33,726			(19,907		)	1,585			—			15,404
	Interest income	—			—			(187		)	—			(187		)
	Income (loss) from continuing operations before taxes	(44,504		)	36,747			51,225			335			43,803
	Taxes (benefit) on income from continuing operations	(15,420		)	17,218			8,832			(2,096		)	8,534
	Equity in net income of consolidated subsidiaries	64,124			43,108			94			(107,326		)	—
	Income from continuing operations	35,040			62,637			42,487			(104,895		)	35,269
	Operating loss from discontinued operations	(25		)	—			—			—			(25		)
	Taxes on loss from discontinued operations	57			—			43			—			100
	Loss from discontinued operations	(82		)	—			(43		)	—			(125		)
	Net income	34,958			62,637			42,444			(104,895		)	35,144
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			186			—			186
	Net income attributable to common shareholders	34,958			62,637			42,258			(104,895		)	34,958
	Other comprehensive income attributable to common shareholders	4,745			7,228			8,523			(15,751		)	4,745
	Comprehensive income attributable to common shareholders	$	39,703		$	69,865		$	50,781		$	(120,646	)	$	39,703
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING BALANCE SHEETS
		March 29, 2015
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	28,102		$	—		$	280,657		$	—		$	308,759
	Accounts receivable, net	3,893			5,176			272,063			3,695			284,827
	Accounts receivable from consolidated subsidiaries	10,159			2,197,884			266,150			(2,474,193		)	—
	Inventories, net	—			206,295			159,769			(27,328		)	338,736
	Prepaid expenses and other current assets	14,965			7,262			18,708			—			40,935
	Prepaid taxes	21,149			—			12,844			—			33,993
	Deferred tax assets	30,248			16,856			9,458			—			56,562
	Assets held for sale	2,901			—			4,058			—			6,959
	Total current assets	111,417			2,433,473			1,023,707			(2,497,826		)	1,070,771
	Property, plant and equipment, net	3,329			172,767			134,010			—			310,106
	Goodwill	—			703,664			589,842			—			1,293,506
	Intangibles assets, net	—			734,111			449,438			—			1,183,549
	Investments in affiliates	5,448,202			1,321,811			20,940			(6,790,219		)	734
	Deferred tax assets	51,316			—			3,968			(54,165		)	1,119
	Notes receivable and other amounts due from consolidated subsidiaries	1,206,846			1,566,089			189			(2,773,124		)	—
	Other assets	29,392			6,836			27,582			—			63,810
	Total assets	$	6,850,502		$	6,938,751		$	2,249,676		$	(12,115,334	)	$	3,923,595
	LIABILITIES AND EQUITY
	Current liabilities
	Current borrowings	$	366,865		$	—		$	34,700		$	—		$	401,565
	Accounts payable	1,645			38,619			35,046			—			75,310
	Accounts payable to consolidated subsidiaries	2,245,622			185,006			43,568			(2,474,196		)	—
	Accrued expenses	18,174			24,052			29,679			—			71,905
	Current portion of contingent consideration	—			7,462			—			—			7,462
	Payroll and benefit-related liabilities	16,836			15,766			33,722			—			66,324
	Accrued interest	12,792			—			63			—			12,855
	Income taxes payable	—			—			17,558			—			17,558
	Other current liabilities	1,672			5,089			4,685			—			11,446
	Total current liabilities	2,663,606			275,994			199,021			(2,474,196		)	664,425
	Long-term borrowings	700,000			—			—			—			700,000
	Deferred tax liabilities	—			438,571			42,362			(54,165		)	426,768
	Pension and other postretirement benefit liabilities	108,627			34,881			19,087			—			162,595
	Noncurrent liability for uncertain tax positions	11,716			15,630			21,988			—			49,334
	Notes payable and other amounts due from consolidated subsidiaries	1,486,644			1,129,731			157,293			(2,773,668		)	—
	Other liabilities	21,976			25,204			12,691			—			59,871
	Total liabilities	4,992,569			1,920,011			452,442			(5,302,029		)	2,062,993
	Total common shareholders' equity	1,857,933			5,018,740			1,794,565			(6,813,305		)	1,857,933
	Noncontrolling interest	—			—			2,669			—			2,669
	Total equity	1,857,933			5,018,740			1,797,234			(6,813,305		)	1,860,602
	Total liabilities and equity	$	6,850,502		$	6,938,751		$	2,249,676		$	(12,115,334	)	$	3,923,595
		December 31, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	27,996		$	—		$	275,240		$	—		$	303,236
	Accounts receivable, net	2,346			2,422			265,081			3,855			273,704
	Accounts receivable from consolidated subsidiaries	37,378			2,303,284			272,811			(2,613,473		)	—
	Inventories, net	—			204,335			154,544			(23,286		)	335,593
	Prepaid expenses and other current assets	14,301			4,786			16,610			—			35,697
	Prepaid taxes	23,493			—			16,763			—			40,256
	Deferred tax assets	30,248			17,387			9,666			—			57,301
	Assets held for sale	2,901			—			4,521			—			7,422
	Total current assets	138,663			2,532,214			1,015,236			(2,632,904		)	1,053,209
	Property, plant and equipment, net	3,489			170,054			143,892			—			317,435
Goodwill	—			703,663			619,890			—			1,323,553
Intangibles assets, net	—			743,222			473,498			—			1,216,720
Investments in affiliates	5,662,773			1,359,661			21,253			(7,042,537		)	1,150
Deferred tax assets	52,244			—			5,535			(56,601		)	1,178
Notes receivable and other amounts due from consolidated subsidiaries	1,025,859			1,489,994			—			(2,515,853		)	—
Other assets	27,999			6,801			29,210			—			64,010
Total assets	$	6,911,027		$	7,005,609		$	2,308,514		$	(12,247,895	)	$	3,977,255
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	363,701		$	—		$	4,700		$	—		$	368,401
Accounts payable	1,449			32,692			29,959			—			64,100
Accounts payable to consolidated subsidiaries	2,259,891			188,908			163,291			(2,612,090		)	—
Accrued expenses	17,149			21,479			33,755			—			72,383
Current portion of contingent consideration	—			11,276			—			—			11,276
Payroll and benefit-related liabilities	20,693			27,228			37,521			—			85,442
Accrued interest	9,152			—			17			—			9,169
Income taxes payable	—			—			13,768			—			13,768
Other current liabilities	5			3,065			7,290			—			10,360
Total current liabilities	2,672,040			284,648			290,301			(2,612,090		)	634,899
Long-term borrowings	700,000			—			—			—			700,000
Deferred tax liabilities	—			462,274			45,867			(56,600		)	451,541
Pension and other postretirement benefit liabilities	110,830			35,074			21,337			—			167,241
Noncurrent liability for uncertain tax positions	11,431			15,569			23,884			—			50,884
Notes payable and other amounts due from consolidated subsidiaries	1,483,984			932,718			103,908			(2,520,610		)	—
Other liabilities	21,433			24,900			12,658			—			58,991
Total liabilities	4,999,718			1,755,183			497,955			(5,189,300		)	2,063,556
Total common shareholders' equity	1,911,309			5,250,426			1,808,169			(7,058,595		)	1,911,309
Noncontrolling interest	—			—			2,390			—			2,390
Total equity	1,911,309			5,250,426			1,810,559			(7,058,595		)	1,913,699
Total liabilities and equity	$	6,911,027		$	7,005,609		$	2,308,514		$	(12,247,895	)	$	3,977,255
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
		Three Months Ended March 29, 2015
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(55,153	)	$	(1,914	)	$	99,425		$	—		$	42,358
	Cash Flows from Investing Activities of Continuing Operations:
	Expenditures for property, plant and equipment	(37		)	(7,738		)	(6,670		)	—			(14,445		)
	Proceeds from sale of assets and investments	—			—			—			—			—
	Payments for businesses and intangibles acquired, net of cash acquired	—			—			(7,375		)	—			(7,375		)
	Net cash used in investing activities from continuing operations	(37		)	(7,738		)	(14,045		)	—			(21,820		)
	Cash Flows from Financing Activities of Continuing Operations:
	Proceeds from long-term borrowings	30,000			—			—			—			30,000
	Repayment of long-term borrowings	(52		)	—			—			—			(52		)
	Net proceeds from share based compensation plans and the related tax impacts	(289		)	—			—			—			(289		)
	Payments for contingent consideration	—			(3,989		)	—			—			(3,989		)
	Dividends	(14,118		)	—			—			—			(14,118		)
	Intercompany transactions	40,057			13,641			(53,698		)	—			—
	Intercompany dividends paid	—			—			—			—			—
	Net cash provided by (used in) financing activities from continuing operations	55,598			9,652			(53,698		)	—			11,552
	Cash Flows from Discontinued Operations:
	Net cash used in operating activities	(302		)	—			(824		)	—			(1,126		)
	Net cash used in discontinued  operations	(302		)	—			(824		)	—			(1,126		)
	Effect of exchange rate changes on cash and cash equivalents	—			—			(25,441		)	—			(25,441		)
	Net increase in cash and cash equivalents	106			—			5,417			—			5,523
	Cash and cash equivalents at the beginning of the period	27,996			—			275,240			—			303,236
	Cash and cash equivalents at the end of the period	$	28,102		$	—		$	280,657		$	—		$	308,759
		Three Months Ended March 30, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(22,185	)	$	24,438		$	39,665		$	—		$	41,918
	Cash Flows from Investing Activities of Continuing Operations:
	Expenditures for property, plant and equipment	(753		)	(4,823		)	(6,533		)	—			(12,109		)
	Proceeds from sales of assets and investments	1,669			—			—			—			1,669
	Payments for business intangibles acquired, net of cash acquired	—			—			(28,991		)	—			(28,991		)
	Investments in affiliates	(60		)	—			—			—			(60		)
	Net cash provided by (used in) investing activities from continuing operations	856			(4,823		)	(35,524		)	—			(39,491		)
	Cash Flows from Financing Activities of Continuing Operations:
	Debt extinguishment, issuance and amendment fees	(90		)	—			—			—			(90		)
	Net proceeds from share based compensation plans and the related tax impacts	323			—			—			—			323
	Dividends	(14,051		)	—			—			—			(14,051		)
	Intercompany transactions	15,776			(28,602		)	12,826			—			—
	Net cash provided by (used in) financing activities from continuing operations	1,958			(28,602		)	12,826			—			(13,818		)
	Cash Flows from Discontinued Operations:													—
	Net cash used in operating activities	(1,167		)	—			—			—			(1,167		)
	Net cash used in discontinued operations	(1,167		)	—			—			—			(1,167		)
	Effect of exchange rate changes on cash and cash equivalents	—			—			2,223			—			2,223
	Net (decrease) increase in cash and cash equivalents	(20,538		)	(8,987		)	19,190			—			(10,335		)
	Cash and cash equivalents at the beginning of the period	42,749			14,500			374,735			—			431,984
	Cash and cash equivalents at the end of the period	22,211			5,513			393,925			—			421,649

Basis_of_presentation_addition

Basis of presentation - additional information (Detail) (Reclassifications, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 30, 2014
Reclassifications
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]
Tax withholding obligations for share based compensation	$8.30

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Jan. 20, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Fair value of the consideration at the date of acquisition				$66,300,000
Net revenues	429,430,000	438,546,000
Income (loss) from continuing operations before taxes	48,605,000	43,803,000
Human Medics
Business Acquisition [Line Items]
Fair value of the consideration at the date of acquisition			8,900,000
Initial payment			7,400,000
Business Combination, Consideration Transferred, Liabilities Incurred			1,800,000
Working capital adjustment related to acquisition	300,000
Transaction expenses	$300,000

Restructuring_and_impairment_c1

Restructuring and impairment charges - additional information (Detail) (USD $)	3 Months Ended		11 Months Ended	13 Months Ended	10 Months Ended	27 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Mar. 29, 2015	Mar. 29, 2015	Mar. 29, 2015	Mar. 29, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$4,448,000	$7,780,000
Impairment charges	0	0
2015 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	4,200,000
Restructuring charges	4,238,000
Restructuring reserve	4,100,000		4,100,000	4,100,000	4,100,000	4,100,000
2015 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	621,000
2015 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	67,000
2015 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2015 Restructuring Program | Minimum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	6,000,000		6,000,000	6,000,000	6,000,000	6,000,000
2015 Restructuring Program | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	7,000,000		7,000,000	7,000,000	7,000,000	7,000,000
2014 Manufacturing Footprint Realignment
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	2,300,000		9,400,000
Restructuring charges	163,000
Restructuring reserve	8,800,000		8,800,000	8,800,000	8,800,000	8,800,000
2014 Manufacturing Footprint Realignment | Accelerated Depreciation And Other Costs
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			7,100,000
Restructuring charges	2,100,000
2014 Manufacturing Footprint Realignment | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Manufacturing Footprint Realignment | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	22,000
2014 Manufacturing Footprint Realignment | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	4,000
2014 Manufacturing Footprint Realignment | Minimum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	37,000,000		37,000,000	37,000,000	37,000,000	37,000,000
Restructuring costs expected cash payment	26,000,000
2014 Manufacturing Footprint Realignment | Minimum | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	11,000,000		11,000,000	11,000,000	11,000,000	11,000,000
2014 Manufacturing Footprint Realignment | Minimum | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	2,000,000		2,000,000	2,000,000	2,000,000	2,000,000
2014 Manufacturing Footprint Realignment | Minimum | Accelerated Depreciation Charges
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	10,000,000		10,000,000	10,000,000	10,000,000	10,000,000
2014 Manufacturing Footprint Realignment | Minimum | Other
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	14,000,000		14,000,000	14,000,000	14,000,000	14,000,000
2014 Manufacturing Footprint Realignment | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	44,000,000		44,000,000	44,000,000	44,000,000	44,000,000
Restructuring costs expected cash payment	31,000,000
2014 Manufacturing Footprint Realignment | Maximum | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	13,000,000		13,000,000	13,000,000	13,000,000	13,000,000
2014 Manufacturing Footprint Realignment | Maximum | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	3,000,000		3,000,000	3,000,000	3,000,000	3,000,000
2014 Manufacturing Footprint Realignment | Maximum | Accelerated Depreciation Charges
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	11,000,000		11,000,000	11,000,000	11,000,000	11,000,000
2014 Manufacturing Footprint Realignment | Maximum | Other
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	17,000,000		17,000,000	17,000,000	17,000,000	17,000,000
2014 European Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring expenses				7,800,000
Restructuring charges	26,000	8,318,000
Restructuring reserve	400,000		400,000	400,000	400,000	400,000
2014 European Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2014 European Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2014 European Restructuring Plan | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	17,000	0
2014 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	49,000				3,600,000
Restructuring reserve	900,000		900,000	900,000	900,000	900,000
2014 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	49,000
2014 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Restructuring Program | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	4,000,000		4,000,000	4,000,000	4,000,000	4,000,000
LMA Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	-31,000	-430,000				11,300,000
Restructuring reserve	100,000		100,000	100,000	100,000	100,000
LMA Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	-31,000	-472,000
LMA Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	42,000
LMA Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	3,000	168,000				11,100,000
Restructuring reserve	800,000		800,000	800,000	800,000	800,000
2013 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2012 Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	6,400,000		6,400,000	6,400,000	6,400,000	6,400,000
Restructuring reserve	$500,000		$500,000	$500,000	$500,000	$500,000

Restructuring_and_impairment_c2

Restructuring and impairment charges (Detail) (USD $)	3 Months Ended		10 Months Ended	27 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Mar. 29, 2015	Mar. 29, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$4,448	$7,780
Total restructuring and impairment charges	4,448	7,780
Termination Benefits
Restructuring Cost And Reserve [Line Items]
Total restructuring and impairment charges	3,699	7,876
Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Total restructuring and impairment charges	89	376
Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Total restructuring and impairment charges	639	-472
Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Total restructuring and impairment charges	21	0
2015 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	4,238
2015 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	3,550
2015 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	67
2015 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	621
2015 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Manufacturing Footprint Realignment
Restructuring Cost And Reserve [Line Items]
Restructuring charges	163
2014 Manufacturing Footprint Realignment | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	137
2014 Manufacturing Footprint Realignment | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	22
2014 Manufacturing Footprint Realignment | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Manufacturing Footprint Realignment | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	4
2014 European Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges	26	8,318
2014 European Restructuring Plan | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9	8,318
2014 European Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2014 European Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2014 European Restructuring Plan | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	17	0
2014 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	49		3,600
2014 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
2014 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	49
2014 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0
LMA Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	-31	-430		11,300
LMA Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
LMA Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	42
LMA Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	-31	-472
LMA Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	3	168		11,100
2013 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	3	168
2013 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2013 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0
2012 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges		-290
2012 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges		-610
2012 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		320
2012 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0
2012 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0
2011 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges		14
2011 Restructuring Plan | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0
2011 Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		14
2011 Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0
2011 Restructuring Plan | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		$0

Restructuring_and_impairment_c3

Restructuring and impairment charges by segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Restructuring and other impairment charges
Total restructuring and impairment charges	$4,448	$7,780
Restructuring charges	4,448	7,780
Vascular North America
Restructuring and other impairment charges
Restructuring charges	830	14
Anesthesia Respiratory North America
Restructuring and other impairment charges
Restructuring charges	-40	27
Surgical North America
Restructuring and other impairment charges
Restructuring charges	23	0
EMEA
Restructuring and other impairment charges
Restructuring charges	-32	7,889
Asia
Restructuring and other impairment charges
Restructuring charges	0	78
OEM
Restructuring and other impairment charges
Restructuring charges	0	0
All Other
Restructuring and other impairment charges
Restructuring charges	$3,667	($228)

Inventories_net_Detail

Inventories, net (Detail) (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$70,285	$68,191
Work-in-process	57,205	58,526
Finished goods	244,814	242,750
Inventories, gross	372,304	369,467
Less: inventory reserve	-33,568	-33,874
Inventories, net	$338,736	$335,593

Goodwill_and_other_intangible_2

Goodwill and other intangible assets, net - additional information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	$1,183,549		$1,216,720
Amortization expense of intangible assets	14,740	16,019
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible asset useful life	7 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible asset useful life	18 years
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	27,600
Trade Names
Finite-Lived Intangible Assets [Line Items]
Intangible assets, net	61,500
Intangible asset useful life	20 years
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	41,000		68,694
In Process Research and Development | Semprus Technology
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$41,000

Goodwill_and_other_intangible_3

Goodwill and other intangible assets, net Changes in carrying amount of goodwill, by reporting segment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill	$1,625,634	$1,655,681
Accumulated impairment losses	-332,128	-332,128
Goodwill	1,293,506	1,323,553
Goodwill related to acquisitions	2,801
Translation adjustment	-32,848
Vascular North America
Goodwill [Roll Forward]
Goodwill	459,696	459,696
Accumulated impairment losses	-219,527	-219,527
Goodwill	240,169	240,169
Goodwill related to acquisitions	0
Translation adjustment	0
Anesthesia Respiratory North America
Goodwill [Roll Forward]
Goodwill	165,998	166,514
Accumulated impairment losses	-107,073	-107,073
Goodwill	58,925	59,441
Goodwill related to acquisitions	0
Translation adjustment	-516
Surgical North America
Goodwill [Roll Forward]
Goodwill	250,912	250,912
Accumulated impairment losses	0	0
Goodwill	250,912	250,912
Goodwill related to acquisitions	0
Translation adjustment	0
EMEA
Goodwill [Roll Forward]
Goodwill	310,488	339,029
Accumulated impairment losses	0	0
Goodwill	310,488	339,029
Goodwill related to acquisitions	0
Translation adjustment	-28,541
Asia
Goodwill [Roll Forward]
Goodwill	143,885	144,712
Accumulated impairment losses	0	0
Goodwill	143,885	144,712
Goodwill related to acquisitions	2,801
Translation adjustment	-3,628
All Other
Goodwill [Roll Forward]
Goodwill	294,655	294,818
Accumulated impairment losses	-5,528	-5,528
Goodwill	289,127	289,290
Goodwill related to acquisitions	0
Translation adjustment	($163)

Goodwill_and_other_intangible_4

Goodwill and other intangible assets, net Components of intangible assets (Details) (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$1,549,695	$1,573,043
Accumulated amortization	-366,146	-356,323
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	616,788	624,574
Accumulated amortization	-196,679	-192,876
Intellectual Property
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	489,857	467,068
Accumulated amortization	-151,521	-146,131
Distribution Rights
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	15,519	16,101
Accumulated amortization	-13,751	-14,243
Trade Names
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	386,194	396,269
Accumulated amortization	-3,858	-2,764
Non-compete Agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	337	337
Accumulated amortization	-337	-309
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	0	0
Indefinite-lived intangible assets	$41,000	$68,694

Goodwill_and_other_intangible_5

Goodwill and other intangible assets, net Annual amortization expense (Details) (USD $)	Mar. 29, 2015
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$43,600
2016	59,500
2017	59,000
2018	58,700
2019	58,400
2020	$58,200

Borrowings_Components_of_longt

Borrowings Components of long-term debt (Details) (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Revolving credit facility, at a rate of 1.92% at March 29, 2015, due 2018	$200,000	$200,000
Total borrowings	1,134,546	1,104,598
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	-32,981	-36,197
Total long-term debt	1,101,565	1,068,401
Current borrowings	-401,565	-368,401
Long-term borrowings	700,000	700,000
3.875% Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
3.875% Convertible Senior Subordinated Notes due 2017	399,846	399,898
6.875% Senior Subordinated Notes due 2019
Debt Instrument [Line Items]
6.875% Senior Subordinated Notes due 2019	250,000	250,000
5.25% Senior Subordinated Notes Due 2024
Debt Instrument [Line Items]
5.25% Senior Notes due 2024	250,000	250,000
Securitization Program
Debt Instrument [Line Items]
Securitization program, at a rate of 0.93% at March 29, 2015	$34,700	$4,700

Borrowings_Additional_Informat

Borrowings - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended
	Mar. 29, 2015	Dec. 31, 2014	Apr. 30, 2015	Dec. 31, 2013	21-May-14	Mar. 30, 2014
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.88%					3.88%
Latest date		28-Jul-17
Total long-term debt	$1,101,565,000	$1,068,401,000
Line of credit facility interest rate	1.92%
Subsequent Event
Debt Instrument [Line Items]
Debt instrument, redemption price percentage			103.44%
Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
Number of trading period		20 days
Number of consecutive trading period		30 days
Threshold percentage of stock price trigger		130.00%
Number of business period		5 days
Principal amount of convertible notes		1,000
Percentage of product of last reported sale price of common stock		98.00%
Conversion ratio		16.3084
Conversion price, per share		$61.32
3.875% Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.88%	3.88%
Debt instrument maturity date	1-Aug-17
6.875% Senior Subordinated Notes due 2019
Debt Instrument [Line Items]
Debt instrument, stated interest rate	6.88%	6.88%
6.875% senior subordinated notes due 2019	250,000,000	250,000,000
Debt instrument maturity date	1-Jun-19			1-Jun-19
6.875% Senior Subordinated Notes due 2019 | Subsequent Event
Debt Instrument [Line Items]
Debt instrument, stated interest rate			6.88%
6.875% senior subordinated notes due 2019			250,000,000
5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, stated interest rate	5.25%	5.25%
Debt instrument maturity date	15-Jun-24				15-Jun-24
Securitization Program
Debt Instrument [Line Items]
Debt instrument, stated interest rate	0.93%

Borrowings_Fair_value_of_long_

Borrowings Fair value of long term debt (Details) (USD $)	Mar. 29, 2015
In Thousands, unless otherwise specified
Fair Value Measurements [Line Items]
Fair value of debt	$1,534,766
Level 1
Fair Value Measurements [Line Items]
Fair value of debt	1,040,170
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$494,596

Financial_instruments_addition

Financial instruments - additional information (Detail) (USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Dec. 31, 2014
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$99,600,000		$0
Amount of gains in accumulated other comprehensive income to be reclassified as expense to the statement of income	100,000
Allowance for doubtful accounts	8,300,000		8,800,000
Current portion of allowance for doubtful accounts	2,300,000		2,400,000
Noncurrent portion of allowance for doubtful accounts	6,000,000		6,400,000
Net revenues	429,430,000	438,546,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Current portion of allowance for doubtful accounts	7,100,000		8,100,000
Net revenues	$33,000,000	$39,300,000

Financial_instruments_Fair_val

Financial instruments Fair values of derivative instruments designated as hedging instruments (Details) (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Derivatives Fair Value [Line Items]
Total asset derivatives	$1,737	$0
Total liability derivatives	1,553	0
Foreign Currency Forward Contract | Prepaid Expenses and Other Current Assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,737	0
Foreign Currency Forward Contract | Other Current Liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$1,553	$0

Financial_instruments_After_ta

Financial instruments After tax (gain)/loss reclassified from accumulated other comprehensive income into income (Details) (Cash Flow Hedging, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Derivatives qualifying as hedges, net of tax	$44	$70
Foreign Currency Forward Contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivatives qualifying as hedges, net of tax	$44	$70

Financial_instruments_Aggregat

Financial instruments Aggregate accounts receivable, net of allowance for doubtful accounts (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 29, 2015		Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long term accounts receivable, allowances	$2,300,000		$2,400,000
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term accounts receivable (net of allowances of $7.1 million and $8.1 million at March 29, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1)	76,322,000	[1]	76,190,000	[1]
Percentage of total net current and long-term accounts receivable	26.60%		27.30%
Current and long term accounts receivable, allowances	7,100,000		8,100,000
Long-term portion of accounts receivable, net	$10,300,000		$11,300,000
[1]	The long-term portion of accounts receivable, net from customers in Greece, Italy, Spain and Portugal at MarchB 29, 2015 and DecemberB 31, 2014 was $10.3 million and $11.3 million, respectively, and is reported on the condensed consolidated balance sheet in other assets

Fair_value_measurement_additio

Fair value measurement - additional information (Detail) (USD $)	Mar. 29, 2015	Dec. 31, 2014
Fair Value Measurements [Line Items]
Fair value measurement with unobservable inputs reconciliations liability value	$29,825,000	$33,433,000
Current portion of contingent consideration	7,462,000	11,276,000
Fair value measurement with unobservable inputs reconciliations other liabilities	22,300,000
Minimum
Fair Value Measurements [Line Items]
Fair value of contingent consideration liability associated with future milestone	11,000,000
Maximum
Fair Value Measurements [Line Items]
Fair value of contingent consideration liability associated with future milestone	$78,932,000

Fair_value_measurement_Financi

Fair value measurement Financial assets and liabilities carried at fair value measured on recurring basis (Details) (USD $)	Mar. 29, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$6,954	$6,863
Derivative assets	1,737
Derivative liabilities	1,553
Contingent consideration liabilities	29,825	33,433
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	6,954	6,863
Derivative assets	0
Derivative liabilities	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	1,737
Derivative liabilities	1,553
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0
Derivative liabilities	0
Contingent consideration liabilities	$29,825	$33,433

Fair_value_measurement_Reconci

Fair value measurement Reconciliation of changes in three financial liabilities measured at fair value on recurring basis (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$33,433
Payment	-4,000
Revaluations	392
Ending balance	$29,825

Fair_value_measurement_Valuati

Fair value measurement Valuation technique and inputs used to determine fair value of assets or liabilities (Details)	3 Months Ended
	Mar. 29, 2015
Probability Of Payment
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration, weighted average	50.20%
Probability Of Payment | Minimum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration	0.00%
Probability Of Payment | Maximum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration	100.00%
Market Approach Valuation Technique [Member]
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration, weighted average	7.30%
Market Approach Valuation Technique [Member] | Minimum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration	1.70%
Market Approach Valuation Technique [Member] | Maximum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration	10.00%

Changes_in_shareholders_equity2

Changes in shareholders' equity - additional information (Details) (USD $)	3 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Jun. 30, 2007	Dec. 31, 2014
Shareholders Equity [Line Items]
Repurchase of outstanding common stock, authorized amount			$300,000,000
Debt instrument, stated interest rate	3.88%	3.88%
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share	5.8	6.5
Convertible Note
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share	3.1	2.5
Per share market price of common stock				$61.32
Strike price of warrents	74.65
Conversion of convertible notes, shares issued upon conversion	2.3	1.6

Changes_in_shareholders_equity3

Changes in shareholders' equity Reconciliation of basic to diluted weighted average common shares outstanding (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Equity [Abstract]
Basic (in shares)	41,469	41,262
Dilutive effect of share-based awards (in shares)	467	471
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	5,359	4,016
Diluted (in shares)	47,295	45,749

Changes_in_shareholders_equity4

Changes in shareholders' equity Change in accumulated other comprehensive income , net of tax (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	($260,895)	($110,855)
Other comprehensive income (loss) before reclassifications	-82,098	4,005
Amounts reclassified from accumulated other comprehensive (loss) income	897	740
Net current-period other comprehensive income (loss)	-81,201	4,745
Ending balance, accumulated other comprehensive income (loss)	-342,096	-106,110
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	0	0
Other comprehensive income (loss) before reclassifications	243	113
Amounts reclassified from accumulated other comprehensive (loss) income	-199	-43
Net current-period other comprehensive income (loss)	44	70
Ending balance, accumulated other comprehensive income (loss)	44	70
Pension and Other Postretirement Benefits Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	-141,744	-97,037
Other comprehensive income (loss) before reclassifications	810	-159
Amounts reclassified from accumulated other comprehensive (loss) income	1,096	783
Net current-period other comprehensive income (loss)	1,906	624
Ending balance, accumulated other comprehensive income (loss)	-139,838	-96,413
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	-119,151	-13,818
Other comprehensive income (loss) before reclassifications	-83,151	4,051
Amounts reclassified from accumulated other comprehensive (loss) income	0	0
Net current-period other comprehensive income (loss)	-83,151	4,051
Ending balance, accumulated other comprehensive income (loss)	($202,302)	($9,767)

Changes_in_shareholders_equity5

Changes in shareholders' equity Accumulated other comprehensive income into income expense (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015		Mar. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$206,793		$217,387
Income from continuing operations before taxes	48,605		43,803
Tax benefit (expense)	-9,332		-8,534
Income from continuing operations	39,273		35,269
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations	897		740
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes	-209		-77
Tax benefit (expense)	10		34
Income from continuing operations	-199		-43
Reclassification out of Accumulated Other Comprehensive Income | Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes	1,606		1,097
Tax benefit (expense)	-510		-314
Income from continuing operations	1,096		783
Actuarial losses	1,606	[1]	1,102	[1]
Prior-service costs	0	[1]	-5	[1]
Reclassification out of Accumulated Other Comprehensive Income | Commodity Contract | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	($209)		($77)
[1]	These accumulated other comprehensive (loss) income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin2

Taxes on income from continuing operations- additional information (Details)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	19.20%	19.50%

Pension_and_other_postretireme2

Pension and other postretirement benefits - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2015
Compensation and Retirement Disclosure [Abstract]
Expected employer contribution for year 2014	$2.90
Employer contribution to pension plan	$1.20

Pension_and_other_postretireme3

Pension and other postretirement benefits Net benefit cost of pension and postretirement benefit plans (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$471	$450
Interest cost	4,486	4,483
Expected return on plan assets	-6,425	-6,260
Net amortization and deferral	1,530	1,071
Net benefit expense (income)	62	-256
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	107	138
Interest cost	512	597
Expected return on plan assets	0	0
Net amortization and deferral	77	26
Net benefit expense (income)	$696	$761

Commitments_and_contingent_lia1

Commitments and contingent liabilities - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
	Dec. 05, 2014	Mar. 29, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Estimated litigation liability		5,000,000
Parish of Calcasieu | Judicial Ruling | Compensatory Damages
Loss Contingencies [Line Items]
Damages awarded	100,000
Parish of Calcasieu | Judicial Ruling | Punitive Damages
Loss Contingencies [Line Items]
Damages awarded	23,000,000
Parish of Calcasieu | Judicial Ruling | Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Possible loss			10,000,000
Discontinued Operations
Loss Contingencies [Line Items]
Estimated litigation liability		1,500,000
Minimum
Loss Contingencies [Line Items]
Time-frame over which the accrued amounts may be paid out, in years		15 years
Maximum
Loss Contingencies [Line Items]
Time-frame over which the accrued amounts may be paid out, in years		20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability		1,100,000
Other Liability
Loss Contingencies [Line Items]
Waste disposed accrued liability		6,500,000

Business_segment_information_a

Business segment information - additional information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015		Mar. 30, 2014		Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$429,430		$438,546
Operating profit	65,608		59,020
Depreciation and amortization	29,850		31,413
Property, plant and equipment, net	310,106				317,435
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	231,206		216,461
Property, plant and equipment, net	177,431				174,893
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	13,441		14,771
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	140,682		168,775
Malaysia
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	36,173				36,427
Czech Republic
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net	32,541				35,655
All Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	44,101		38,539
Property, plant and equipment, net	63,961				70,460
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	83,654	[1]	81,717	[1]
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	-18,046	[2]	-22,697	[2]
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	67,913		62,506
Depreciation and amortization	8,477		7,855
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	12,702		9,392
Anesthesia Respiratory North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	55,390		54,714
Depreciation and amortization	3,195		4,428
Anesthesia Respiratory North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	7,752		5,687
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	38,059		35,231
Depreciation and amortization	2,478		2,369
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	12,327		10,548
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	129,282		150,245
Depreciation and amortization	7,898		8,937
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	26,335		26,881
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	48,529		49,602
Depreciation and amortization	2,398		1,838
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	8,146		12,837
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	34,715		33,182
Depreciation and amortization	1,667		1,456
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	8,043		6,604
All Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	55,542		53,066
Depreciation and amortization	3,737		4,530
All Other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$8,349		$9,768
[1]	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
[2]	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges.

Condensed_consolidating_guaran2

Condensed consolidating guarantor financial information - additional information (Detail) (USD $)	Mar. 29, 2015	Mar. 30, 2014	Jun. 26, 2011
In Thousands, unless otherwise specified
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	3.88%	3.88%
Ownership percentage of subsidiaries	100.00%
6.875% Senior Subordinated Notes due 2019
Condensed Financial Statements Captions [Line Items]
6.875% Senior Subordinated Notes due 2019			$250,000
Debt instrument, stated interest rate			6.88%

Condensed_consolidating_guaran3

Condensed consolidating guarantor financial information Condensed consolidating statements of income and comprehensive income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Condensed Income Statements, Captions [Line Items]
Net revenues	$429,430	$438,546
Cost of goods sold	206,793	217,387
Gross profit	222,637	221,159
Selling, general and administrative expenses	139,697	140,297
Research and development expenses	12,884	14,062
Restructuring and impairment charges	4,448	7,780
Income from continuing operations before interest and taxes	65,608	59,020
Interest expense	17,172	15,404
Interest income	-169	-187
Income from continuing operations before taxes	48,605	43,803
Taxes (benefit) on income from continuing operations	9,332	8,534
Equity in net income of consolidated subsidiaries	0	0
Income from continuing operations	39,273	35,269
Operating (loss) income from discontinued operations	-499	-25
Taxes on loss from discontinued operations	204	100
Loss from discontinued operations	-703	-125
Net income	38,570	35,144
Less: Income from continuing operations attributable to noncontrolling interests	218	186
Net income attributable to common shareholders	38,352	34,958
Other comprehensive loss attributable to common shareholders	-81,201	4,745
Comprehensive (loss) income attributable to common shareholders	-42,849	39,703
Consolidation, Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	-93,632	-72,316
Cost of goods sold	-89,151	-72,854
Gross profit	-4,481	538
Selling, general and administrative expenses	160	203
Research and development expenses	0	0
Restructuring and impairment charges	0	0
Income from continuing operations before interest and taxes	-4,641	335
Interest expense	0
Interest income	0	0
Income from continuing operations before taxes	-4,641	335
Taxes (benefit) on income from continuing operations	2,829	-2,096
Equity in net income of consolidated subsidiaries	-132,868	-107,326
Income from continuing operations	-140,338	-104,895
Operating (loss) income from discontinued operations	0	0
Taxes on loss from discontinued operations	0	0
Loss from discontinued operations	0	0
Net income	-140,338	-104,895
Less: Income from continuing operations attributable to noncontrolling interests	0	0
Net income attributable to common shareholders	-140,338	-104,895
Other comprehensive loss attributable to common shareholders	183,051	-15,751
Comprehensive (loss) income attributable to common shareholders	42,713	-120,646
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0
Cost of goods sold	0	0
Gross profit	0	0
Selling, general and administrative expenses	11,452	10,778
Research and development expenses	0	0
Restructuring and impairment charges	0	0
Income from continuing operations before interest and taxes	-11,452	-10,778
Interest expense	34,360	33,726
Interest income	0	0
Income from continuing operations before taxes	-45,812	-44,504
Taxes (benefit) on income from continuing operations	-15,293	-15,420
Equity in net income of consolidated subsidiaries	69,538	64,124
Income from continuing operations	39,019	35,040
Operating (loss) income from discontinued operations	-503	-25
Taxes on loss from discontinued operations	164	57
Loss from discontinued operations	-667	-82
Net income	38,352	34,958
Less: Income from continuing operations attributable to noncontrolling interests	0	0
Net income attributable to common shareholders	38,352	34,958
Other comprehensive loss attributable to common shareholders	-81,201	4,745
Comprehensive (loss) income attributable to common shareholders	-42,849	39,703
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	264,161	262,425
Cost of goods sold	158,326	152,368
Gross profit	105,835	110,057
Selling, general and administrative expenses	84,268	81,395
Research and development expenses	11,127	12,010
Restructuring and impairment charges	3,739	-188
Income from continuing operations before interest and taxes	6,701	16,840
Interest expense	-18,569	-19,907
Interest income	0	0
Income from continuing operations before taxes	25,270	36,747
Taxes (benefit) on income from continuing operations	10,992	17,218
Equity in net income of consolidated subsidiaries	63,233	43,108
Income from continuing operations	77,511	62,637
Operating (loss) income from discontinued operations	0	0
Taxes on loss from discontinued operations	0	0
Loss from discontinued operations	0	0
Net income	77,511	62,637
Less: Income from continuing operations attributable to noncontrolling interests	0	0
Net income attributable to common shareholders	77,511	62,637
Other comprehensive loss attributable to common shareholders	-106,761	7,228
Comprehensive (loss) income attributable to common shareholders	-29,250	69,865
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	258,901	248,437
Cost of goods sold	137,618	137,873
Gross profit	121,283	110,564
Selling, general and administrative expenses	43,817	47,921
Research and development expenses	1,757	2,052
Restructuring and impairment charges	709	7,968
Income from continuing operations before interest and taxes	75,000	52,623
Interest expense	1,381	1,585
Interest income	-169	-187
Income from continuing operations before taxes	73,788	51,225
Taxes (benefit) on income from continuing operations	10,804	8,832
Equity in net income of consolidated subsidiaries	97	94
Income from continuing operations	63,081	42,487
Operating (loss) income from discontinued operations	4	0
Taxes on loss from discontinued operations	40	43
Loss from discontinued operations	-36	-43
Net income	63,045	42,444
Less: Income from continuing operations attributable to noncontrolling interests	218	186
Net income attributable to common shareholders	62,827	42,258
Other comprehensive loss attributable to common shareholders	-76,290	8,523
Comprehensive (loss) income attributable to common shareholders	($13,463)	$50,781

Condensed_consolidating_guaran4

Condensed consolidating guarantor financial information Condensed consolidating balance sheets (Details) (USD $)	Mar. 29, 2015	Dec. 31, 2014	Mar. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$308,759	$303,236	$421,649	$431,984
Accounts receivable, net	284,827	273,704
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	338,736	335,593
Prepaid expenses and other current assets	40,935	35,697
Prepaid taxes	33,993	40,256
Deferred tax assets	56,562	57,301
Assets held for sale	6,959	7,422
Total current assets	1,070,771	1,053,209
Property, plant and equipment, net	310,106	317,435
Goodwill	1,293,506	1,323,553
Intangible assets, net	1,183,549	1,216,720
Investments in affiliates	734	1,150
Deferred tax assets	1,119	1,178
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	63,810	64,010
Total assets	3,923,595	3,977,255
Current liabilities
Current borrowings	401,565	368,401
Accounts payable	75,310	64,100
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	71,905	72,383
Current portion of contingent consideration	7,462	11,276
Payroll and benefit-related liabilities	66,324	85,442
Accrued interest	12,855	9,169
Income taxes payable	17,558	13,768
Other current liabilities	11,446	10,360
Total current liabilities	664,425	634,899
Long-term borrowings	700,000	700,000
Deferred tax liabilities	426,768	451,541
Pension and other postretirement benefit liabilities	162,595	167,241
Noncurrent liability for uncertain tax positions	49,334	50,884
Notes payable and other amounts due from consolidated subsidiaries	0	0
Other liabilities	59,871	58,991
Total liabilities	2,062,993	2,063,556
Total common shareholders' equity	1,857,933	1,911,309
Noncontrolling interest	2,669	2,390
Total equity	1,860,602	1,913,699	1,945,227	1,916,016
Total liabilities and equity	3,923,595	3,977,255
Consolidation, Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	3,695	3,855
Accounts receivable from consolidated subsidiaries	-2,474,193	-2,613,473
Inventories, net	-27,328	-23,286
Prepaid expenses and other current assets	0	0
Prepaid taxes	0	0
Deferred tax assets	0	0
Assets held for sale	0	0
Total current assets	-2,497,826	-2,632,904
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in affiliates	-6,790,219	-7,042,537
Deferred tax assets	-54,165	-56,601
Notes receivable and other amounts due from consolidated subsidiaries	-2,773,124	-2,515,853
Other assets	0	0
Total assets	-12,115,334	-12,247,895
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	-2,474,196	-2,612,090
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	0	0
Total current liabilities	-2,474,196	-2,612,090
Long-term borrowings	0	0
Deferred tax liabilities	-54,165	-56,600
Pension and other postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due from consolidated subsidiaries	-2,773,668	-2,520,610
Other liabilities	0	0
Total liabilities	-5,302,029	-5,189,300
Total common shareholders' equity	-6,813,305	-7,058,595
Noncontrolling interest	0	0
Total equity	-6,813,305	-7,058,595
Total liabilities and equity	-12,115,334	-12,247,895
Parent Company
Current assets
Cash and cash equivalents	28,102	27,996	22,211	42,749
Accounts receivable, net	3,893	2,346
Accounts receivable from consolidated subsidiaries	10,159	37,378
Inventories, net	0	0
Prepaid expenses and other current assets	14,965	14,301
Prepaid taxes	21,149	23,493
Deferred tax assets	30,248	30,248
Assets held for sale	2,901	2,901
Total current assets	111,417	138,663
Property, plant and equipment, net	3,329	3,489
Goodwill	0	0
Intangible assets, net	0	0
Investments in affiliates	5,448,202	5,662,773
Deferred tax assets	51,316	52,244
Notes receivable and other amounts due from consolidated subsidiaries	1,206,846	1,025,859
Other assets	29,392	27,999
Total assets	6,850,502	6,911,027
Current liabilities
Current borrowings	366,865	363,701
Accounts payable	1,645	1,449
Accounts payable to consolidated subsidiaries	2,245,622	2,259,891
Accrued expenses	18,174	17,149
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	16,836	20,693
Accrued interest	12,792	9,152
Income taxes payable	0	0
Other current liabilities	1,672	5
Total current liabilities	2,663,606	2,672,040
Long-term borrowings	700,000	700,000
Deferred tax liabilities	0	0
Pension and other postretirement benefit liabilities	108,627	110,830
Noncurrent liability for uncertain tax positions	11,716	11,431
Notes payable and other amounts due from consolidated subsidiaries	1,486,644	1,483,984
Other liabilities	21,976	21,433
Total liabilities	4,992,569	4,999,718
Total common shareholders' equity	1,857,933	1,911,309
Noncontrolling interest	0	0
Total equity	1,857,933	1,911,309
Total liabilities and equity	6,850,502	6,911,027
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	0	0	5,513	14,500
Accounts receivable, net	5,176	2,422
Accounts receivable from consolidated subsidiaries	2,197,884	2,303,284
Inventories, net	206,295	204,335
Prepaid expenses and other current assets	7,262	4,786
Prepaid taxes	0	0
Deferred tax assets	16,856	17,387
Assets held for sale	0	0
Total current assets	2,433,473	2,532,214
Property, plant and equipment, net	172,767	170,054
Goodwill	703,664	703,663
Intangible assets, net	734,111	743,222
Investments in affiliates	1,321,811	1,359,661
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	1,566,089	1,489,994
Other assets	6,836	6,801
Total assets	6,938,751	7,005,609
Current liabilities
Current borrowings	0	0
Accounts payable	38,619	32,692
Accounts payable to consolidated subsidiaries	185,006	188,908
Accrued expenses	24,052	21,479
Current portion of contingent consideration	7,462	11,276
Payroll and benefit-related liabilities	15,766	27,228
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	5,089	3,065
Total current liabilities	275,994	284,648
Long-term borrowings	0	0
Deferred tax liabilities	438,571	462,274
Pension and other postretirement benefit liabilities	34,881	35,074
Noncurrent liability for uncertain tax positions	15,630	15,569
Notes payable and other amounts due from consolidated subsidiaries	1,129,731	932,718
Other liabilities	25,204	24,900
Total liabilities	1,920,011	1,755,183
Total common shareholders' equity	5,018,740	5,250,426
Noncontrolling interest	0	0
Total equity	5,018,740	5,250,426
Total liabilities and equity	6,938,751	7,005,609
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	280,657	275,240	393,925	374,735
Accounts receivable, net	272,063	265,081
Accounts receivable from consolidated subsidiaries	266,150	272,811
Inventories, net	159,769	154,544
Prepaid expenses and other current assets	18,708	16,610
Prepaid taxes	12,844	16,763
Deferred tax assets	9,458	9,666
Assets held for sale	4,058	4,521
Total current assets	1,023,707	1,015,236
Property, plant and equipment, net	134,010	143,892
Goodwill	589,842	619,890
Intangible assets, net	449,438	473,498
Investments in affiliates	20,940	21,253
Deferred tax assets	3,968	5,535
Notes receivable and other amounts due from consolidated subsidiaries	189	0
Other assets	27,582	29,210
Total assets	2,249,676	2,308,514
Current liabilities
Current borrowings	34,700	4,700
Accounts payable	35,046	29,959
Accounts payable to consolidated subsidiaries	43,568	163,291
Accrued expenses	29,679	33,755
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	33,722	37,521
Accrued interest	63	17
Income taxes payable	17,558	13,768
Other current liabilities	4,685	7,290
Total current liabilities	199,021	290,301
Long-term borrowings	0	0
Deferred tax liabilities	42,362	45,867
Pension and other postretirement benefit liabilities	19,087	21,337
Noncurrent liability for uncertain tax positions	21,988	23,884
Notes payable and other amounts due from consolidated subsidiaries	157,293	103,908
Other liabilities	12,691	12,658
Total liabilities	452,442	497,955
Total common shareholders' equity	1,794,565	1,808,169
Noncontrolling interest	2,669	2,390
Total equity	1,797,234	1,810,559
Total liabilities and equity	$2,249,676	$2,308,514

Condensed_consolidating_guaran5

Condensed consolidating guarantor financial information Condensed consolidating statements of cash flows (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	$42,358	$41,918
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	-14,445	-12,109
Proceeds from sale of assets and investments	0	1,669
Payments for businesses and intangibles acquired, net of cash acquired	-7,375	-28,991
Investments in affiliates	0	-60
Net cash used in investing activities from continuing operations	-21,820	-39,491
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	30,000	0
Repayment of long-term borrowings	-52	0
Debt extinguishment, issuance and amendment fees	0	-90
Net proceeds from share based compensation plans and the related tax impacts	-289	323
Payments for contingent consideration	-3,989	0
Dividends	-14,118	-14,051
Intercompany transactions	0	0
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	11,552	-13,818
Cash Flows from Discontinued Operations:
Net cash used in operating activities	-1,126	-1,167
Net cash used in discontinued operations	-1,126	-1,167
Effect of exchange rate changes on cash and cash equivalents	-25,441	2,223
Net decrease in cash and cash equivalents	5,523	-10,335
Cash and cash equivalents at the beginning of the period	303,236	431,984
Cash and cash equivalents at the end of the period	308,759	421,649
Consolidation, Eliminations
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	0	0
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets and investments	0	0
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates		0
Net cash used in investing activities from continuing operations	0	0
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	0
Repayment of long-term borrowings	0
Debt extinguishment, issuance and amendment fees		0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0
Dividends	0	0
Intercompany transactions	0	0
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	0	0
Cash Flows from Discontinued Operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	-55,153	-22,185
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	-37	-753
Proceeds from sale of assets and investments	0	1,669
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates		-60
Net cash used in investing activities from continuing operations	-37	856
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	30,000
Repayment of long-term borrowings	-52
Debt extinguishment, issuance and amendment fees		-90
Net proceeds from share based compensation plans and the related tax impacts	-289	323
Payments for contingent consideration	0
Dividends	-14,118	-14,051
Intercompany transactions	40,057	15,776
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	55,598	1,958
Cash Flows from Discontinued Operations:
Net cash used in operating activities	-302	-1,167
Net cash used in discontinued operations	-302	-1,167
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	106	-20,538
Cash and cash equivalents at the beginning of the period	27,996	42,749
Cash and cash equivalents at the end of the period	28,102	22,211
Guarantor Subsidiaries
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	-1,914	24,438
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	-7,738	-4,823
Proceeds from sale of assets and investments	0	0
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates		0
Net cash used in investing activities from continuing operations	-7,738	-4,823
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	0
Repayment of long-term borrowings	0
Debt extinguishment, issuance and amendment fees		0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	-3,989
Dividends	0	0
Intercompany transactions	13,641	-28,602
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	9,652	-28,602
Cash Flows from Discontinued Operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	0	-8,987
Cash and cash equivalents at the beginning of the period	0	14,500
Cash and cash equivalents at the end of the period	0	5,513
Non-Guarantor Subsidiaries
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	99,425	39,665
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	-6,670	-6,533
Proceeds from sale of assets and investments	0	0
Payments for businesses and intangibles acquired, net of cash acquired	-7,375	-28,991
Investments in affiliates		0
Net cash used in investing activities from continuing operations	-14,045	-35,524
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	0
Repayment of long-term borrowings	0
Debt extinguishment, issuance and amendment fees		0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0
Dividends	0	0
Intercompany transactions	-53,698	12,826
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	-53,698	12,826
Cash Flows from Discontinued Operations:
Net cash used in operating activities	-824	0
Net cash used in discontinued operations	-824	0
Effect of exchange rate changes on cash and cash equivalents	-25,441	2,223
Net decrease in cash and cash equivalents	5,417	19,190
Cash and cash equivalents at the beginning of the period	275,240	374,735
Cash and cash equivalents at the end of the period	$280,657	$393,925